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Abstract 
Consideration of the elderly as a special population in pharmacological treatment is often 
overlooked. The consequence of this is an increased likelihood of therapeutic failure or 
adverse drug effects in elderly patients. Particularly given the huge disease burden and 
challenges with clinical trial recruitment in this population, the development and 
utilization of approaches that allow better understanding of pharmacological differences 
in older patients is important. This dissertation aimed to use model-based approaches to 
examine and characterize age-related differences in the drug disposition and tolerability 
of topiramate and gabapentin, two neurology drugs commonly used in elderly patients. In 
alignment with the support for model-based drug development in the elderly population, 
a modeling and simulation tool that helps facilitate the workflow of pharmacometrics 
tasks was also developed, as part of this dissertation.  
Based on data pooled from three randomized, crossover studies in healthy subjects, we 
characterized the relationship between topiramate plasma concentration and cognitive 
impairment, as measured by the Symbol Digit Modality Test (SDMT) using population 
pharmacokinetic-pharmacodynamic modeling. In this analysis, both age and number of 
prior test administered were important determinants of the baseline SDMT score, with an 
estimated decrease of 1.13% in baseline SDMT score per year increase in age, and 7% 
improvement in test scores after two prior testing. Differences in sensitivity to cognitive 
effect of topiramate based on age, could not be discerned.  
In the population pharmacokinetic analysis of gabapentin, data comprising of a wide 
range of renal function and ages from patients (aged 18 years and above) was pooled and 
the effects of factors such as renal function, age, dose, total daily dose etc. on 
pharmacokinetic parameters examined, with the objective of providing more information 
for dosing recommendations, especially in elderly. This data was sufficiently described 
by a one-compartment pharmacokinetic model, with saturable absorption of gabapentin 
characterized through a nonlinear function of dose on the extent of absorption. Similar to 
earlier reports, gabapentin clearance was dependent on renal function in this analysis, and 
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there was no additional effect of age on clearance after this has been accounted for in the 
model. In addition, no pharmacokinetic differences between nursing home and 
community dwelling elderly were found, and no improvement in the model fit was 
observed with inclusion of age as a covariate on other parameters. Hence, from this 
analysis, no adjustment of dose by age in adults appears to be warranted.   
Lastly, we developed the R package, Phxnlme, as an auxiliary tool to address existing 
limitations in the population pharmacokinetic/pharmacodynamics software, Phoenix 
NLME. With the development and sharing of this R package on a public repository, 
additional ease is now provided for checking of model assumptions and exploring 
relationships in the output through graphical visualization. Furthermore, users will also 
be able to multi-task modeling activities using Phoenix NLME through the use of this R 
package. This is a functionality that was not readily available with the use of Phoenix 
NLME as a desktop software. Through this R package release, we hope to facilitate use 
of model-based drug development, particularly in the elderly population. In line with this, 
video demonstrations for use of the R package was made and a manual for its use is 
provided.  
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1.1 Challenges in pharmacotherapy in the elderly 
Globally, the number of individuals age 65 years and over is expected to more than 
double, from 524 million in 2010 to more than 2 billion in 2050, representing 16% of the 
world’s population (1). While there is no clear consensus, the elderly population is often 
arbitrarily defined as individuals aged 65 years and older. This is in part influenced by the 
standard retirement age. For the purpose of providing appropriate clinical guidance in 
elderly patients, this threshold however may not be informative. Wide differences can 
exist within individuals of the same chronological age, and it has been suggested that 
physiological age or frailty may be considered to help optimize medication prescription 
in this population (2–4). However, there is currently no clear consensus on an operational 
definition and measure of frailty and physiological age.  
In general, aging is linked to a number of changes such as change in body composition, 
absorption, hepatic, renal, cognitive functions and cardiovascular system, which can 
impact pharmacotherapy in this rapidly expanding elderly population. This is further 
complicated by the fact that older adults are more prone to adverse drug effects, possibly 
due to existing co-morbidities and/or the multiple concomitant medications that they are 
taking, which can increase the risk of adverse drug-drug interactions (DDIs). Table 1 
shows the common co-morbidities in the elderly.  
Despite these complicating factors and the disproportionately larger health burden in this 
vulnerable population, elderly patients tend to be under-represented in clinical trials, 
making it challenging to provide appropriate pharmacotherapeutic recommendations, 
even in disease areas where they are the primary population afflicted (5–7). In a recent 
review, it was found that although 60% of cancer patients are older than 65 years, on 
average only about 33% of patients included in registration trials of approved cancer 
therapies from 2007 to June 2010 attained this age (8). Similarly for cardiovascular 
disease, while mean age of Medicare beneficiaries was 74.7 years, the mean age of 
cardiovascular clinical trial participants was only 60.1 years (9). In Alzheimer's disease, 
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despite the substantial rise in incidence of the disease over age 75 years, mean age of 
clinical trial participants was lower than that (10,11). Other areas where clinical trial 
participation of elderly patients have been reported to be low include epilepsy, 
depression, pain and incontinence (2,6,12,13).  
This long-standing issue with under-representation of elderly in clinical trials, especially 
those with multiple co-morbidities, is multifaceted and has been attributed to a number of 
reasons. These range from medical factors such as higher risk of adverse events and co-
morbidities that may confound the trial, to trial logistic issues like difficulties with 
transportation which may impede ability to participate, compliance, lack of insurance, 
and communication problems which may limit feasibility of phone interviews (5,14–16). 
Extra caution also needs to be taken to obtain informed consent, especially for cognitive 
impaired individuals 
1.1.1 Regulatory proponents to address the challenges 
The importance of geriatric clinical data and the consensus that not all potential 
differences in pharmacokinetics, pharmacodynamics, disease-drug interactions, DDIs, 
and clinical response that can occur in the elderly population can be predicted from non-
elderly populations, has been emphasized by regulatory agencies (17,18). As highlighted 
in the International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) E7 guidance established in 1993, 
“drugs should be studied in all age groups, including the elderly, for which they will have 
significant utility”, and clinical trial participants should be “reasonably representative of 
the population that will be later treated by the drug” (19). Both the US Food and Drug 
Administration (FDA) and European Medicines Agency (EMA) have subsequently also 
published supporting documents to expand on the ICH guidance. Recommendations from 
the EMA include increasing elderly patients participation in clinical development 
programs, with the requirement for the “proportion of efficacy and safety database to 
mirror the target population”, and the use of population pharmacokinetic approach to 
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assess and characterize differences (if any) between elderly and younger subjects (20). 
Likewise, FDA recommends “appropriate representation of the geriatric population 
(including patients with concomitant therapies and co-morbidities) to adequately 
characterize efficacy and safety in the geriatric population and allow for comparisons 
with the non-geriatric population”. The use of population pharmacokinetic analysis to 
identify age-related differences not explained by other factors, such as reduced renal 
function or weight differences, was also suggested, provided “sufficient  number of 
patients in different age ranges (including patients >65 and >75 years) are included in the 
clinical trials” (17).  
As a follow-up, initiatives are being taken to re-evaluate the current age threshold for 
elderly (arbitrarily defined as 65 years in ICH E7 guidance) and to more clearly define 
and reliably assess frailty (20,21). Recommendations for the ethical aspects of clinical 
trials, addressing the issues of informed consent and geriatric expertise on research ethics 
committee, have also been recently published by the Geriatric Medicine Working Party 
of the European Forum for Good Clinical Practice (22).  
1.1.2 Pharmacokinetic considerations  
As mentioned in the ICH E7 guidance, impairment of renal and hepatic functions in the 
elderly are often important contributors of pharmacokinetic differences between younger 
adults and elderly patients (19). Besides these, other age-related physiological changes 
may also affect the pharmacokinetic characteristics (absorption, distribution, metabolism 
and elimination) of a drug and these are important points for consideration when treating 
elderly patients. 
Absorption 
Age-related physiological changes in the gastrointestinal tract can lead to an impact on 
the extent and/or the rate of absorption of oral drugs in the elderly. For example, 
reduction of gastric acid secretion, which has been associated with aging, may influence 
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absorption of drugs that are sensitive to pH (e.g., ketoconazole and atazanavir), and 
possible decreases in gut motility can potentially affect the maximal drug concentration 
observed (Cmax) and time at which Cmax is observed (tmax) (14,23). Whilst in some cases, 
age itself may not be causative (e.g., gastric acid secretion decline may be due to higher 
rates of atrophic gastritis or usage of proton pump inhibitors, and changes in motility 
could be confounded by co-morbidities and co-medications that are commonly used in 
elderly), examination for absorption differences in the elderly would still be relevant (24–
26). This is particularly true for drugs with limited permeability and solubility. For drugs, 
with high permeability, absorption is limited mostly by gastrointestinal blood flow, which 
could be reduced in old age (14,27). 
Distribution 
Changes in body composition occurring with age may affect drug distribution. With 
advancing age, lean body mass and total body water gradually decreases and there is a 
relative increase in body fat (28,29). These changes can result in an increased volume of 
distribution for lipophilic drugs and hence longer elimination half-life (if there is no 
change in clearance), and vice versa for hydrophilic drugs (14,30). Besides this, age-
related changes in protein binding (e.g. reduction in blood albumin and increase in α1-
acid glycoprotein, likely secondary to malnutrition, co-existing disease and co-
medications in the elderly) may also affect drug distribution, and hence half-life 
(14,30,31). However, the clinical relevance of changes in protein binding (i.e. effect on 
unbound area-under-curve [AUC]) is generally low, except for high extraction ratio drugs 
given intravenously and oral drugs eliminated by non-hepatic high extraction ratio routes 
(32).  Nonetheless, consideration of disease or DDI-related change in protein-binding 
may be important in the case where total instead of unbound concentration was used in 
therapeutic drug monitoring. It should also be noted that aging, as well as diseases 
common in old age, have been reported to alter permeability of the blood-brain barrier, 
and this may alter distribution of certain drugs to the brain (33). 
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Metabolism 
Advancing age is associated with reduction in hepatic blood flow and liver mass (34). 
Consistent with this, for drugs with clearance that is blood flow-limited, it has been found 
that clearance is reduced with age, and this reduction correlates well with the age-related 
decline in blood flow (34).  Phase II metabolism has not been found to change with age 
(34). On the other hand, there are reports that clearance of drugs metabolized via phase I 
pathways appears to be affected by age, even though in vitro activity of phase I enzymes 
remain unchanged with age in general (35–39). It has been suggested that this clearance 
reduction is probably due to a combination of reduced hepatic blood flow and reduced 
hepatic volume (40). As a result, drug metabolism may be substantially reduced in the 
elderly, leading to reduced hepatic clearance and higher drug exposure and 
bioavailability. In addition, factors such as smoking, alcohol consumption, coexisting 
diseases and certain drugs (e.g. erythromycin, amiodarone) can also inhibit hepatic 
enzymes and further impair drug metabolism (41–43). 
Elimination 
Renal changes, such as decline in glomerular filtration rate and tubular function, 
accompanying advanced age are very important factors to consider in geriatric 
pharmacotherapy, specifically for drugs with low therapeutic indices that are eliminated 
via the renal route (e.g. digoxin, gentamicin and lithium) (14). Notably, other than the 
age-associated decline in renal function, co-morbidities such as hypertension, diabetes 
and congestive heart failure that are common in the elderly, are also factors that affect 
renal function (44,45).   
1.1.3 Pharmacodynamic considerations  
Overall, the effect of advancing age on pharmacodynamics is hard to generalize since it is 
highly dependent on the drug studied and the processes underlying aging, which are still 
not fully understood. Furthermore, lack of consideration for pharmacokinetic differences 
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and/or other confounding factors that may affect the pharmacodynamic endpoint (e.g. co-
medications and co-morbidities) may be an issue. Nonetheless, pharmacodynamic 
differences in the elderly have so far been more commonly reported for drugs that affect 
the central nervous system and cardiovascular system (46). For instance, increased 
sedative effect of flunitrazepam and reduced response to beta-adrenergic agents (14,46–
49).  
In general, pharmacodynamic differences related to age are less frequently observed than 
pharmacokinetic ones, and in line with this, a recently published summary of the 
discussion between regulators from the three ICH regions advised that specific clinical 
studies by age group are typically not required, unless suggested by early data and past 
experience (e.g., CNS-active drugs such as sedating anti-histamines) (50). Further 
recommendation for the use of modeling to assist in exploration of a relationship with age 
was also given in this publication.  
1.2 Neurological disorders in the elderly 
With the rapid growth of the elderly population, neurological disorders, which occur 
frequently in older adults, is an important concern (51,52). Other than stroke and 
neurodegenerative disorders such as Alzheimer's disease and Parkinson’s disease, 
epilepsy and neuropathic pain are two other major health problems affecting the elderly 
(52–54).  
1.2.1 Epilepsy in the elderly population  
According to a recent revision by the International League Against Epilepsy, epilepsy is a 
disease of the brain defined by any of the following conditions – (1) at least two 
unprovoked (or reflex) seizures occurring >24 h apart, (2) one unprovoked (or reflex) 
seizure and a probability of further seizures similar to the general recurrence risk (at least 
60%) after two unprovoked seizures, occurring over the next 10 years, or (3) diagnosis of 
an epilepsy syndrome (identified by common clinical and electrical characteristics) (55). 
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This disorder is known to be more likely to develop in the elderly compared to younger 
individuals, with reported annual incidence of 76 per 100 000 in those aged 60–69 years, 
and more than 147 per 100 000 in those aged 70 years and above, versus an incidence of 
69 per 100 000 across other age groups (53,56–58). With the global expansion in the 
elderly population, these numbers are expected to further increase, resulting in greater 
healthcare burden. To exacerbate this, older adults tend to be more susceptible to co-
morbidities of epilepsy, such as physical injuries, depression and anxiety (53,59,60).   
As discussed earlier, pharmacotherapy in the elderly population is challenging. This is 
particularly true for the treatment of epilepsy in the elderly, since anti-seizure drugs often 
have cognitive side effects and are prone to DDIs (61–63). Furthermore, the frequent 
presence of cognitive impairment in this populace, complicated by old age and different 
seizure types and loci, also makes it difficult to isolate and quantify the cognitive effects 
of the anti-seizure drugs. 
1.2.2 Neuropathic pain in the elderly population  
Neuropathic pain, which is defined as pain arising as a direct consequence of a lesion or 
disease affecting the somatosensory system, is another known health burden that has a 
greater tendency to affect the elderly population (64). This is highlighted in a large cross-
sectional study of patients with chronic neuropathic pain in Europe, where 49.8% of the 
patients were 65 years or older (65). Similarly, this age-biased trend can be seen in a 
shingles clinical study (n=916), where 18% of patients in their 50s experienced 
symptoms of neuropathic pain for one year or longer, compared to 48% in patients aged 
70 and above. Age-associated rise in incidence of other diseases that cause neuropathic 
pain (e.g. diabetes mellitus, herpes zoster, low back pain, many cancers, limb amputation, 
and stroke) has often been cited as the reason for this disparity (66). 
In general, there is a paucity of data on neuropathic pain, especially in older adults, which 
could be contributed by the perception that pain is part of the ageing process, as well as 
the challenges related to pain assessment in the elderly e.g. hearing, vision and cognition 
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problems (54,67). However, limited studies have found that despite receiving treatment, 
patients reported significant pain levels that interferes daily functioning, underscoring the 
need for better management of neuropathic pain (65,68).  
1.3 Pharmacometrics  
Pharmacometrics is a multidisciplinary science that quantifies drug, disease and trial 
information, with the aim to aid efficient drug development, and regulatory and 
therapeutic decisions (69,70). These include optimization of dosing regimen, more 
informed and efficient clinical trial design and acceleration of drug development (e.g. by 
providing model-based evidence) (71). Various approaches are commonly utilized within 
this field to achieve these goals. For example, population pharmacokinetic modeling is 
used to describe the overall drug concentration time course and the sources of variability, 
population pharmacokinetic-pharmacodynamic modeling is used to describe the 
concentration-effect relationship and quantify/explain variability, and disease progression 
modeling is used to describe the time courses of disease markers following active 
treatment and placebo/no treatment. With these models established, clinical trial 
simulations allow comparison of different trial designs and scenarios based on these 
models.  
1.3.1 Utility of pharmacometric analyses in drug evaluation in the elderly 
population 
While increasing participation of elderly in clinical trials is an obvious way to address the 
issue with paucity of information for dosing in elderly, as outlined earlier, this is 
challenging due to the logistics and very importantly, the higher prevalence of risk factors 
for adverse events. An approach to mitigate risk of exposure of a vulnerable population to 
investigational products and allow the studying of age-related effects in a minimally 
invasive manner is to utilize pharmacometric tools such as modeling and simulation 
(72,73).  
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As mentioned, the use of population pharmacokinetics modeling has been encouraged by 
regulatory agencies. One advantage of the population approach (i.e., mixed effect 
modeling), in this special population, is that it allows the quantification and evaluation of 
the sources of variability in this highly heterogeneous group, hence impact of patient 
characteristics and physiological parameters on pharmacokinetics and pharmacodynamics 
can be investigated and included in dosing recommendations if needed. For example, 
through population pharmacokinetic-pharmacodynamic modeling, Minto et al. found an 
effect of age and lean body weight on both pharmacokinetic and pharmacodynamics 
factors of remifentanil (74). Subsequent simulations further demonstrated the importance 
of considering these covariates in the dosing regimen, and recommendations were made 
for reduction of the bolus dose and infusion rate of remifentanil administered to elderly 
(74). The current dosing label of remifentanil reflects this recommendation and suggests 
that starting dose in patients over 65 years of age should be decreased by 50% (75). In the 
case of duloxetine, population pharmacokinetic analysis revealed sex, age, smoking 
status and ethnicity as significant covariates, but based on large overlaps in drug 
exposures between the patient subgroups, demonstrated through simulations, specific 
dose recommendations based on these factors were not warranted (76). Other than the 
possibility of direct impact on dosing recommendations, the understanding of variability 
in pharmacokinetics, drug or placebo response, gained through such analyses can also be 
leveraged for optimization of future study designs (e.g. reduce unnecessarily large sample 
sizes) and to determine the feasibility of the development of an investigational drug 
product. 
Classical pharmacokinetic methods often require dense sampling from each individual, 
which is a challenge with elderly due to sampling capacity limitations, missed visits (due 
to transportation issues, acute ailments etc.), dropouts (due to transportation issues, 
ailments, death etc.) and difficulty with recruitment. With the population approach, 
sparse individual data from all the patients can be utilized to build a structural model, 
which provides the typical values of the model parameters, and estimates of random 
effects, which include inter-individual variability in the model parameters and residual 
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unexplained variability,. An advantage of this approach is that it allows the pooling of 
data across different studies and phases of drug development. For example, densely 
sampled data from phase I studies (typically in healthy and younger subjects) may, in 
some cases, be pooled with data from typically more sparsely sampled but larger phase 
II/III studies, that are conducted in a more heterogeneous and ‘real-world’ population. In 
addition, data across different studies and treatments could also be pooled and potentially 
leveraged for future trial design, rational dose selection and development of new 
therapeutics, through building of meta-based disease progression models (77). This is 
especially beneficial for older adults since progressive diseases like Alzheimer's disease, 
Parkinson’s disease and Type II diabetes are common in this age group. Through the 
establishment of reliable disease progression models, the need for long (for slow 
progressing diseases) and large studies, both being major challenges in elderly patients, is 
reduced.    
One key concern regarding pharmacotherapy in the elderly population that has often been 
cited as an important reason to improve participation of older adults in clinical trials is 
the risk of DDIs. Traditionally, investigation of potential DDI is carried out during phase 
I studies in healthy volunteers, guided by in vitro data, as well as by clinical case reports 
in the post-marketing phase. While useful, the former approach is only feasible for 
exploration of interactions predictable from in vitro methods and the latter does not offer 
sufficient understanding of the potential interactions (78). In contrast, a population-based 
approach allows quantification of potential or known DDIs, as well as detection of 
unanticipated interactions. For example, through population-based approach applied on 
routine clinical data, 12 drugs with previously unreported/unconfirmed interactions with 
cyclosporine were identified (79). Three-quarter of these had common metabolic or 
transport pathway as cyclosporine, which provided likely explanations for the observed 
interactions (79). Furthermore, as the population analyses can be performed with sparse 
data collected during phase II/III of clinical drug development, when implemented in 
addition to the traditional methods, a better glimpse of potentially important clinical 
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DDIs in the target population can be obtained prior to postmarketing surveillance, 
without having to conduct additional studies.  
Besides the population approach, advancement in the area of pharmacometrics has also 
enabled physiologically-based pharmacokinetic (PBPK) models to be built from vast 
human physiologic, genetic and epidemiological data, that when combined with in vitro 
and clinical data, allows for much better prediction of DDIs. Moreover, with the 
incorporation of known physiological information, virtual patient populations are 
available in PBPK simulation software such as Simcyp, to help predict pharmacokinetic 
changes in special populations such as pediatrics, pregnant women, and patients with 
organ impairment (80,81). While this is currently unavailable for the elderly population, 
with better understanding and characterization of changes and the variability in this 
population, such predictions could potentially be available for the elderly as well.  
Similar to the case with pediatrics, which is another special population with challenges in 
sampling, recruitment and ethical considerations, efforts are being made to better 
capitalize on the predictive value of pharmacometric analyses for the elderly population 
thus reducing the need for exposing a large number of vulnerable patients to 
investigational drugs. Towards this end, case studies are increasingly being shared and 
strategies proposed for bridging the evidence gap for safe and effective use of medicines 
in the elderly. One such case study published by the FDA demonstrated the use of 
population pharmacokinetic modeling and risk-benefit acceptability threshold analysis to 
obtain the exposure range that allows maintenance of antipsychotic efficacy of duloxetine 
with minimal risk of glucose intolerance in older patients (82). A decision tree was also 
recently proposed to guide decisions on the type of analyses and studies that need to be 
conducted to obtain appropriate dosing information (Figure 1) (73). For example, if a 
drug is intended for a different indication in the elderly population, it is recommended 
that efficacy and safety studies be conducted in this group, and population 
pharmacokinetic analysis can be done to evaluate impact of DDIs and renal/hepatic 
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impairment and other covariates on the pharmacokinetics. This strategic framework is 
relevant for ongoing drug development as well as analyses post-approval. 
1.3.2 Pharmacometrics software 
1.3.3 NONMEM 
Developed in the 1980s by Stuart Beal, Lewis Sheiner, and Alison Boeckmann, NON-
linear Mixed Effect Modeling software package (NONMEM) was the first available 
nonlinear mixed-effects modeling program for pharmacokinetic and pharmacodynamic 
analysis, and it has remained most widely used for population analysis (83–86). Based on 
maximum likelihood theory, various approximation methods within NONMEM (e.g. first 
order approximation (FO), first order conditional approximation (FOCE) and Laplace 
approximation) are available for the computation and minimization of the objective 
function (−2 log likelihood of the model parameters given the data). With more recent 
updates of the software, more estimation methods (e.g. iterative two-stage (ITS), 
importance sampling expectation-maximization (IMP), stochastic approximation 
expectation-maximization (SAEM), and Markov-chain Monte-Carlo (MCMC) bayesian 
analysis) have also been added to NONMEM. 
NONMEM, which is a Fortran-compiled program, is largely non-interactive and is 
typically either executed from the command line or through graphical user interface-
based (GUI) applications such as Pirana, PDx-POP and Census (87–89). The output from 
NONMEM mainly consists of list files (e.g. summary file) and tabular output (e.g. 
individual records of prediction), although diagnostic scatterplots (e.g. observation versus 
prediction) can also be requested. The latter utilizes dated graphical technique and cannot 
be rescaled or adjusted, hence is seldom used. Instead, external programs like R, SAS and 
S-Plus are often used to post-process the output (e.g. extract the final estimates for reports 
and produce graphical model diagnostics). Notably, the R package, Xpose, is popular for 
post-processing of NONMEM output (90). Additionally, tools such as Perl-speaks-
 14 
 
NONMEM (PsN) are also often used with NONMEM for a variety of pharmacometric 
analysis tasks that include bootstraps, visual predictive checks (VPCs) and various 
covariate modeling approaches.       
1.3.4 Phoenix NLME 
Phoenix NLME, a population modeling software that was developed more recently, is 
part of a suite of tools that includes WinNonlin for noncompartmental analysis and an in 
vitro - in vivo correlation analysis tool (IVIVC) (91). In contrast with NONMEM, 
Phoenix NLME provides an integrated workflow-based environment for modeling and 
simulation, with a GUI comprising of drop-down menus and checkboxes for selection of 
different modeling options, which is more user friendly, especially for novice modelers. 
Other advantages of this program include analysis traceability, visual workflow for 
project organization and the ability to build a model that is not available in their library 
via graphical or textual means. While built-in graphical diagnostics for models are 
automatically generated, making it easier for users to do model assumption checking and 
assess the model performance, there is however limited customizability of the output, 
which can be an issue for commonly used and published model evaluation output such as 
the visual predictive check. Furthermore, the desktop version of this software is unable to 
perform simultaneous model runs, which is a major issue that limits productivity.      
1.3.5 R 
R is a programming language and environment for statistical computing and graphics 
(92). It is available as a free software and offers numerous functions ranging from data 
manipulation to a broad spectrum of graphical and statistical functions (e.g. linear and 
nonlinear modelling, classical statistical tests, clustering and time-series analysis). One 
key strength of R is that it provides an open-source and integrated environment for all 
these data analysis steps to be performed. Furthermore, the flexibility and ease with 
which additional functionalities can be added to it, through writing of new functions and 
 15 
 
packages (collections of R functions and data that can be easily shared), is a major 
advantage. This extensibility and the popularity of such a feature is evident from the large 
number of packages (i.e. over 7000 user-contributed packages) that have been developed 
and shared. Out of this large list of R packages, Xpose, metrumrg, PKgraph, PKreport, 
PKPDmodels, SAEMIX and Phxnlme (details of development presented in Chapter 4) 
are examples of some packages that have been developed for pharmacometrics, and 
ggplot2, lattice, dplyr, survival, R2winbugs and nlme are a few packages that were not 
specifically developed for pharmacometrics, but are often utilized within this discipline 
(90,93–102).  
Besides these, other strengths of R include the high-quality graphics that can be produced 
and the huge pool of free learning/help resources available for both R users and R 
package developers (e.g. R help/documentation, forums, blogs, online books, and 
learning resources shared by academic institutes). While R has shortcoming in its 
efficiency for computationally-intensive tasks, it has been suggested that this can be 
overcome through utilizing its ability to integrate with other languages such as C, C++ 
and Fortran (92).  
1.4 Aims and Scope of dissertation research 
Understanding of the effects of aging and the related physiological changes on 
pharmacokinetics and pharmacodynamics is critical for benefit-risk assessment and 
optimization of dosing for drugs that will be used in the elderly. The lack of consideration 
for such effects can lead to increased likelihood of therapeutic failure or suboptimal 
safety/efficacy of medicines in elderly patients. Given the large burden of neurological 
disorders on the elderly and the highlighted challenges with pharmacotherapy in this 
population, it is critical to develop and utilize approaches that allow better understanding 
of the differences when a drug is used in patients with advanced age, without over-
exposing this vulnerable population to risk. In support of these efforts, the overall goal of 
this dissertation was to use model-based approaches to examine and characterize the 
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effect of age and various physiological factors, such as renal function, on the 
pharmacokinetics and tolerability of topiramate and gabapentin, two neurology drugs 
commonly used in the elderly. Aligned with the support for model-based drug 
development in the elderly population, another aim of this dissertation was to develop a 
modeling and simulation tool that helps facilitate the workflow of pharmacometrics tasks 
and hence contribute to the drive of model-based drug development. 
1.4.1 Pharmacokinetic-pharmacodynamic modeling of the cognitive effect of 
topiramate on adult healthy volunteers: The role of age and practice 
Topiramate is an anti-seizure medication that is increasingly being prescribed for a range 
of other conditions including migraine prophylaxis, obesity, and pain (103–106). Prior 
study of the pharmacokinetics of topiramate in elderly (age 65 to 85) and younger adults 
found approximately 20% higher topiramate exposures in elderly patients. Analyses 
indicated that differences between age group was no longer significant after accounting 
for creatinine clearance (measure of renal function) (107). This is consistent with a 
known general decline in renal function with age, and the dependency of topiramate on 
renal excretion (14,108). In a population pharmacokinetic study comprising of patients 
with a wide range of renal function, influence of renal function on clearance of the drug 
was similarly reported (109). In contrast, renal function was not a significant covariate on 
clearance in another population pharmacokinetic study conducted in patients with normal 
renal function (110).  
Although topiramate pharmacokinetics has been characterized in elderly patients, little is 
known about its tolerability in this population. In younger patients, cognitive adverse 
effects are a major concern for topiramate, with report of almost 50% of discontinuations 
due to cognitive adverse events, in a retrospective analysis of 470 patients with epilepsy 
(111). In the elderly, it is expected that the severity of this issue would be further 
magnified (112). Elderly patients may be more vulnerable to cognitive impairment due to 
generally diminished cognitive reserve when compared with younger adults, and many 
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often take other medications that may have cognitive side effects. Despite suggestions 
that older individuals may be more susceptible to topiramate-induced cognition deficit, 
there is currently no clear evidence on whether they respond differently from younger 
subjects. Moreover, the relationship between plasma topiramate levels and cognition 
impairment has not been fully investigated. To fill this gap in knowledge and optimize 
topiramate therapy in the elderly, characterization of the relationship between topiramate 
dose, plasma topiramate levels and cognitive impairment, and the exploration of 
covariates such as age, is needed. The objective of Chapter 2 was to describe these 
relationships in a disease-free population (to avoid confounding variables such as 
seizures, drug interactions and the underlying pathology of epilepsy), across a wide age 
range. In addition, the effect of repeated administration of the neuropyschological test, 
namely the Symbol Digit Modalities Test was also explored and included in the 
pharmacokinetic-pharmacodynamic model reported in the following chapter.     
1.4.2 Pooled population pharmacokinetic analysis of gabapentin in the elderly and 
younger adult patients 
Gabapentin ([1-(aminomethyl)cyclohexaneacetic acid], Neurontin®) is indicated for the 
adjunctive treatment of partial seizures and is the first-line treatment agent for 
neuropathic pain conditions such as diabetic neuropathy, post-herpetic neuralgia and 
central pain (113). It is a commonly used medication in older adults and is often favored 
for its low risk of DDIs, and lack of serious cognitive and other adverse events, which are 
two typical concerns when treating elderly patients with anti-seizure medications 
(114,115).  
However, while gabapentin is not appreciably metabolized and hence is unsusceptible to 
hepatic impairment and CYP-mediated drug interactions, it is substantially excreted by 
the kidney and its elimination is dependent on renal function. Due to general decline in 
renal function with age, this has potential implications on gabapentin dosing in the 
elderly. In terms of absorption, gabapentin is known to display nonlinearity across the 
 18 
 
usual clinical dose range (up to 2400 to 3600 mg/day), due likely to saturable intestinal 
transport (14,116). This saturable transport had been previously characterized in younger 
adults and a preliminary population pharmacokinetic analysis of gabapentin in nursing 
home elderly patients (117–119). The latter reported saturation of gabapentin absorption 
at a lower dose than that reported in the former younger adults study, suggesting that 
given the same oral dose of gabapentin, less drug may get absorbed by the nursing home 
elderly patient and this may result in reduced efficacy.  
Currently, dose reduction recommendations are based only on creatinine clearance 
(measure of renal function) and not age, since an analysis based on a small range of renal 
function found no additional effect of age on clearance, after creatinine clearance had 
been accounted. Re-examination of this in a population with a wider range of renal 
function and age would be useful. Also, while the effect of age on saturable absorption 
had been suggested, further investigation is needed. In Chapter 3, we sought to address 
these concerns through population pharmacokinetic modeling of a large pooled 
gabapentin dataset with a wide range of dose, age and renal function. In addition, the 
availability of relatively large numbers of nursing home and community dwelling elderly 
patients also allowed the opportunity to explore differences in this two populations.   
1.4.3 Phxnlme: an R package that facilitates pharmacometrics workflow of 
Phoenix NLME analyses 
The value of pharmacometric approaches, particularly in special populations such as the 
elderly has been demonstrated and highlighted. Due to the quantitative nature of these 
approaches, computational aspects such as reliability of the modeling and simulation 
software/estimation methods, ease of implementation and learning of the software, and 
ease with which key tasks (e.g. model development and communication) can be 
performed, are important factors that influence the use of modeling and simulation.  
Very often, the pharmacometrics workflow can involve multiple computational platforms 
for the execution of different procedures such as data management and exploration, 
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modeling, model diagnostics/evaluation, simulation and reporting, and multiple iterations 
of such processes are usually needed. To aid with this, various auxiliary tools and 
interface have been developed for the popular nonlinear mixed effects modeling software, 
NONMEM. However, such auxiliary tools are currently lacking in Phoenix NLME, 
another popular software used in this discipline. In Chapter 4, this need is addressed 
through the development of the R package, Phxnlme, the first Phoenix NLME-
compatible auxiliary R package to be developed and released open-source. The aim of 
this package development was to address some of the current limitations with the 
Phoenix NLME GUI (e.g. deficiency with post-processing and multi-tasking capability), 
as well as to provide an integrated platform for key model development activities. Other 
than description of the functionalities that were created for these key modeling tasks (e.g. 
basic model diagnostics, visual predictive checks and bootstraps), Chapter 4 also takes 
the gabapentin pharmacokinetic model that was developed in Chapter 3 using 
NONMEM, as an example to illustrate the utilities of the Phxnlme R package.  
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Figure 1.1 Example of a decision tree to aid drug development in the elderly 
population. Reproduced with permission from “Rational use of medicines in older 
adults: Can we do better during clinical development?” Saeed et al., 2015. Clinical 
Pharmacology & Therapeutics 97(5): 440-443.  
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Table 1.1 Common morbidities in older adults.  
Hypertension Stroke 
Hyperlipidemia Chronic pain 
Ischemic heart disease Falls 
Diabetes Urinary incontinence 
Arthritis Herpes zoster and postherpetic 
neuralgia 
Heart failure Visual impairment 
Depression Hearing impairment 
Chronic kidney disease Gastroesophageal reflux disease 
Osteoporosis Parkinson’s disease 
Alzheimer's disease Insomnia 
Chronic obstructive pulmonary disease  
Cancer  
Data from Mayo Clin Proc. 2010 Mar;85(3 Suppl):S26-32 and Epidemiol Rev. 
2013;35:75-83. doi: 10.1093/epirev/mxs009. 
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CHAPTER 2                                                                
PHARMACOKINETIC-PHARMACODYNAMIC MODELING 
EFFECT OF COGNITIVE EFFECT OF TOPIRAMATE ON ADULT 
HEALTHY VOLUNTEERS: EFFECT OF AGE AND MULTIPLE 
TESTING 
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2.1 Introduction 
Topiramate, a sulfamate-substituted monosaccharide, is a second-generation anti-seizure 
drug initially approved by the FDA for partial-onset and primary generalized tonic-clonic 
seizures. It was later approved for migraine prophylaxis and this is now its major use in 
the USA. More recently, it was approved for obesity (in combination with phentermine), 
and is also increasingly prescribed for a wide range of conditions including pain, bipolar 
disorder, and substance abuse.  
Topiramate is associated with cognitive and language adverse effects severe enough to 
cause a higher rate of discontinuation of therapy when compared to other second-
generation anti-seizure drugs (1–4). Reported from studies in patients with epilepsy, the 
incidence of cognitive complaints associated with topiramate usage is highly variable (3-
44%) (4–7). Though this variability may be attributed, in part, to differences in titration 
rate, maintenance dose, and the underlying etiologies of epilepsy, the relationship 
between topiramate exposure and cognitive impairment has not been fully investigated 
(8). 
In both patients and healthy adults, topiramate administration has been shown to produce 
concentration-related declines in generative and discourse-level verbal fluency, working 
memory and attention (3,9,10). Given the role of working memory in the production of 
fluent speech, it is not surprising that, along with measures of verbal fluency, the Symbol 
Digit Modalities Test (SDMT), which requires elements of working memory, attention, 
and psychomotor speed, is one of the neuropsychological tests most sensitive to the 
cognitive effects of topiramate (10–15).  For instance, using only a single, 100 mg dose 
of topiramate in healthy volunteers, topiramate plasma concentration was found to have 
the largest impact on both the SDMT as well as tests of verbal fluency (10).  However, 
there are no studies that provide a quantitative assessment for the exposure-response 
relationship between topiramate plasma levels and SDMT performance (10).  
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The objective of this analysis was to quantify the effects of a single-dose of topiramate 
(100 or 200 mg) on working memory, attention and psychomotor speed as measured by 
the SDMT.  In order to isolate the cognitive effects of topiramate from those possibly 
arising from an underlying medical condition, subjects were healthy adults.  Using both 
oral and a novel stable-labeled intravenous (IV) formulation of topiramate developed by 
our group, we utilized a sequential pharmacokinetic-pharmacodynamics (PK-PD) 
modeling approach to characterize the topiramate plasma concentration – SDMT score 
relationship, and to explore the effects of age, repeated administration of the cognitive 
test, and other possible covariates that may influence this relationship.  
2.1 Methods 
2.1.1 Subjects   
Native English-speaking healthy volunteers between 18 and 65 years of age were 
recruited from two sites, University of Minnesota (UMN) and University of Florida (UF).  
Exclusion criteria included histories of significant cardiovascular, endocrine, 
hematopoietic, hepatic, neurologic, psychiatric, or renal disease, current or a history of 
drug or alcohol abuse within the past five years, use of concomitant medications known 
to affect topiramate or alter cognitive function, use of any investigational drug or device 
within 30 days prior to screening, a diagnosis of language impairment/disability, 
uncorrected low vision, and history of intolerance to intravenous administration of 
medication.  Eligible subjects underwent a brief physical and neurological examination. 
Subjects were expected to have normal renal function as they were healthy, nonelderly 
adults with no reported history of renal disease. 
The study protocols were approved by the UMN and UF Institutional Review Boards and 
subjects provided written informed consents prior to enrollment. 
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2.1.2 Study Designs 
Data pooled from three randomized crossover studies were used to build the PK-PD 
model. Information about date of birth, race, ethnicity, sex, height, weight, and medical 
and surgical history was collected at the screening visit. The PD assessment consisted of 
a neuropsychological battery that included tests of working memory, attention and 
psychomotor speed (i.e., SDMT), as well as recall and generative and discourse level 
verbal fluency. This battery was administered to the subjects during all visits. Only the 
scores from the SDMT were modeled in this paper. Results from the verbal fluency and 
recall tasks have been previously published (9,16). 
Study I 
Study I (UMN) was a 2-period crossover bioequivalence study of IV and oral topiramate. 
Two subjects were administered 50 mg of IV topiramate infused over 15 min, followed 
by 50 mg of oral topiramate after a two-week washout period. The remaining 10 subjects 
were randomly assigned to receive a single dose of 100 mg IV or oral topiramate in the 
first period, followed by the alternate route of administration in the second period after a 
two-week washout. Blood samples for measurement of topiramate plasma concentration 
levels were collected pre-dose, and at 5, 15, 30 min and 1, 2, 4, 6, 10, 12, 24, 48, 72, 96, 
and 120 hr post-dose. Baseline SDMT scores were collected the day prior to treatment 
period 1 dosing, as well as at the end of treatment period 2 (following a two-week 
washout). During period 1 and 2, SDMT was administered at 0.25, 2 and 6 hr post-dose. 
SDMT scores were only available for the 100 mg dose group but PK data from the 50 mg 
group were included in the PK model. 
Study II 
Study II (UF) was a randomized, double blind, placebo-controlled 2-period crossover 
study. Subjects were administered 100 mg oral topiramate or placebo in the first period 
and the alternate treatment in the second period following a one-week washout. Baseline 
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SDMT scores were collected one week prior to period 1, and one week following period 
2 dosing. During each dosing period, SDMT was administered approximately 1 to 1.5 hr 
post-dose, and a single blood sample was drawn for measurement of topiramate plasma 
concentrations immediately after the cognitive function test. Topiramate plasma 
concentration levels were also measured at baseline visits to ensure complete washout.   
Study III 
Study III (UMN) was a randomized, double-blind, placebo-controlled, 3-period crossover 
study, with the same pharmacokinetic sampling and SDMT score administration schedule 
as Study II. Either 100 mg or 200 mg oral topiramate was administered during the 
treatment period. The additional periods consisted of treatment with a single 2 mg dose of 
a comparator (lorazepam) or placebo.   
2.1.3 Plasma Topiramate Measurement 
Blood samples from Study I were analyzed using a validated liquid chromatography-
mass spectrometry (LC-MS) method, with lower limit of quantification of 0.04 µg/ml 
(17). For Study II and III, topiramate concentrations were quantified by a validated LC-
MS developed for simultaneous determination of nine anti-seizure drugs. Lower limit of 
quantification was 0.375 µg/ml (18).   
2.1.4 Symbol-Digit Modalities Test  
The SDMT is a cognitive performance measure of psychomotor speed, working memory 
and attention (19). It consists of a key containing nine unique symbols corresponding to 
the numbers 1 to 9, and a list of random symbols, for which the subjects are required to 
match to the numbers according to the key. The number of symbols coded correctly 
within 90 seconds represents the score. To ensure the subjects understood the instructions 
prior to the start of the test, a short standardized practice trial was given. Four (4) 
alternate versions of the SDMT were used in order to minimize the practice effect.  
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2.1.5 Population Pharmacokinetics-Pharmacodynamics Modeling 
Population modeling of topiramate plasma concentrations and SDMT scores was 
performed using nonlinear mixed effects modeling with the NONMEM version 7.2 
software (ICON Development Solutions, Hanover, MD, USA). Diagnostic graphics and 
exploratory analyses were performed using R (version 3.1.0) and Xpose (version 4.3.2). 
The population PK model of oral and IV topiramate used in this analysis has been 
previously described (16). Individual empirical Bayesian estimates of the 
pharmacokinetic parameters from the established PK model were used to model the 
topiramate plasma concentration-SDMT score relationship. SDMT score, which consist 
of the number of correctly coded symbols within the test duration (i.e., 90 seconds), can 
be treated as either approximately continuous data or discrete count data, so both 
distributional assumptions were explored. For the latter, three different distributional 
models were fitted: i) Poisson, which assumes that the expected number of counts is 
equal to the variance of the counts within an individual i.e. equidispersion, ii) Negative 
Binomial, which allows for overdispersion and iii) Generalized Poisson, which allows for 
either over- or under-dispersion (20,21).  
The relationship between topiramate plasma concentration and SDMT score change was 
explored using three basic functions: i) linear, ii) exponential/log-linear and iii) Emax as 
follows: 
ܧపఫ෢ ൌ ܧ0௜ െ ݇௜ ∙ ܥ݌௜௝    (1) 
ܧపఫ෢ ൌ ܧ0௜ െ exp	ሺ݇௜ ∙ ܥ݌௜௝ሻ   (2) 
ܧపఫ෢ ൌ ܧ0௜ ∙ ሺ1 െ ா௠௔௫೔∙஼௣೔ೕா஼ହ଴೔ା	஼௣೔ೕሻ   (3) 
where ܧపఫ෢  and Cpij denote the jth predicted SDMT score and predicted topiramate plasma 
concentration respectively of the ith individual. ki is the slope, and E0i, Emaxi and EC50i 
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are the baseline SDMT score, maximal fractional reduction in SDMT score due to drug 
effect and concentration at half of the maximal drug effect, respectively, of the ith 
individual.   
Individual pharmacodynamic parameters were assumed to be log-normally distributed 
and the interindividual random effects were modeled using an exponential error structure. 
Goodness of fit of the final model was evaluated using graphical assessment and 
histograms of the empirical Bayes predictions of the interindividual random effects were 
also inspected to verify that the statistical assumptions were met (i.e. unimodal and 
symmetrically distributed around zero). 
2.1.6 Covariate assessment 
To investigate the potential effect of age, study and sex on the PD parameters (E0, EC50 
and Emax), these covariates were each tested separately to determine if they should be 
included in the final model using the stepwise forward inclusion and backward 
elimination approach. The criterion for forward inclusion and backward elimination was 
an OFV decrease of at least 3.84 for 1 degree of freedom (p< 0.05) and increase of at 
least 6.63 for 1 degree of freedom (p< 0.01) respectively. The impact of continuous 
covariates on the PD parameters was explored using linear, exponential and power 
models, with the covariate scaled/centered by the median value. Categorical covariates 
were included as discrete indicator variables. To explore practice effect within an 
individual, the number of prior tests administered (NPT) was included as a dichotomous 
covariate on baseline SDMT score as shown in Equation 4: 
ܧ0 ൌ 	ܸܶܧ0 ∗ ሺI୒୔୘ஸ୬ ൅ I୒୔୘வ୬ ∗ Θ୒୔୘வ୬ሻ  (4) 
N is {0,1,…,6}, INPT≤n and INPT>n are indicator variables (0/1) for whether the number of 
prior test is less than or equals to n or exceeds n (i.e. this allows cutoff at the nth prior test 
for comparison of the baseline scores that had greater than n tests preceding it (NPT > n), 
with baseline scores from all tests before that (0 < NPT ≤ n), and ΘNPT>n denotes the 
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proportionality constant for the change in baseline scores, when NPT exceeds n. Different 
cutoff points were explored, starting with a cutoff of NPT>0, and departure of the 95% 
CI of ΘNPT>n from the null value of 1, indicated significant difference.  
2.1.7 Model Selection and Assessment 
Model selection was based on difference in NONMEM objective function value (OFV) 
for competing nested models using the likelihood ratio test, graphical diagnostics using 
goodness-of-fit (GOF) plots, precision of parameter estimates and plausibility of the 
parameter estimates. Akaike’s Information Criterion (AIC) was considered for non-
nested models. Evaluation of the final model was performed by prediction-corrected 
visual predictive checks (pc-VPC), using Perlspeaks-NONMEM (PsN) (version 3.6.2), 
based on 1000 simulations (22).  
Precision of the final model parameter estimates was assessed using both the asymptotic 
standard errors obtained by the covariance routine in NONMEM, and nonparametric 
bootstrap performed using PsN. From the original dataset, 1000 bootstrap datasets were 
constructed by repeated sampling with replacement and the final model was fitted to each 
of the bootstrap dataset. The median and the 2.5th and 97.5th percentiles were then 
obtained for each PD parameter and 95% confidence intervals based on the percentiles 
obtained.  
2.2 Results 
2.2.1 Demographics 
The final dataset consisted of a total of 189 SDMT scores from 38 healthy volunteers 
(n=30 for 100 mg and n=8 for 200 mg). Median age across the studies was 26.5 years, 
ranging from 19 to 55 years. The demographic characteristics of the population included 
in the PK-PD analysis are summarized in Table 2.1, stratified by study.  
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2.2.2 Continuous distributional model 
The topiramate exposure-SDMT relationship was adequately described by a direct 
response inhibitory Emax model, with treatment of SDMT data as a continuous variable. 
As shown in Figure 2.1 (upper panel), distribution of the observed SDMT scores was 
approximately normal, indicating adequacy in treatment of the SDMT data as continuous 
data. The parameters of this final model were also well estimated with RSE of less than 
30% and shrinkage values of less than 10%. A summary of the population parameter 
estimates from the final PK-PD model and the corresponding relative standard errors 
(RSE) are provided in Table 2.2.  
Out of the three structural models (linear, exponential and inhibitory Emax function 
models) that were explored, the Emax model provided the best fit, with AIC of 1114.8, 
compared to the exponential and linear models (1123.4 and 1118.8 respectively). 
Interindividual random effects for Emax and EC50 could not be reliably estimated, hence 
the base model only included interindividual random effect on the baseline parameter, 
E0. 
With an increase in age, a trend towards a decrease in baseline SDMT score was 
observed (Figure 2.2). The inclusion of age as a covariate on baseline SDMT score in the 
model improved the fit significantly (decrease in OFV of 18.15; p<0.005), and explained 
24% of the interindividual variability in baseline SDMT, relative to the final base model.  
When exploring the effect of administering multiple tests on SDMT scores collected 
under drug-free conditions (pre- and post-treatment baselines and placebo observations), 
there appeared to be an improvement in test scores (Figure 2.3). Starting with a cutoff of 
NPT>0, the 95% CI for the estimate of ΘNPT included the null value of 1, indicating no 
significant difference between the first test score (NPT=0) and subsequent ones (NPT>0). 
At a cutoff of NPT>1, a 7% improvement in SDMT score was estimated, with significant 
departure of ΘNPT from 1 (95% CI: 1.02 to 1.14). This inclusion of NPT>1 as a covariate 
also resulted in a significant drop in OFV (6.91; p<0.01). Subsequent cutoffs (e.g., 
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NPT>2, NPT>3 and so on) were similarly tested and no clear trend in improvement 
beyond NPT larger than 1 was observed. Sex, race and study did not have a significant 
effect on either the E0, EC50 or Emax. The final model is represented by Equation 5: 
ܧ௜௝ ൌ 	ܧ0௜ ∗ Θ୒୔୘வଵ ∗ ቀ1 ൅ Θୟ୥ୣ ∗ ൫ܽ݃݁௜	 െ ݉݁݀݅ܽ݊	ܽ݃݁൯ቁ ∗ ൬1 െ ா௠௔௫೔∗஼௣೔ೕா஼ହ଴೔ା	஼௣೔ೕ൰ ∗ ሺ1 ൅
ߝ௜௝ሻ (5) 
where Eij  and Cpij are the jth SDMT score and jth predicted topiramate plasma 
concentration respectively of the ith individual, E0i, Emaxi and EC50i are the baseline 
SDMT score of the ith individual.  ΘNPT>1 is the proportionality constant accounting for 
difference in E0 for NPT greater than 1, and is 1 when NPT is less than or equal to 1, Θage 
is the effect of age on E0 and εij is the residual error. 
2.2.3 Discrete distributional model 
Exploration of count data models (Poisson, Generalized Poisson and Negative Binomial) 
in this analysis did not yield an improvement of fit to the data, and results were generally 
similar to that from the model assuming continuous distribution As shown in Table 2.2, 
parameter estimates and their precision were similar for the model assuming continuous 
data and the Poisson model. For the models that allow for non-equidispersion 
(Generalized Poisson and Negative Binomial), parameter estimates for baseline and 
effect of age and NPT on baseline were comparable to those from the model assuming 
continuous data. However, the dispersion parameter of the Generalized Poisson model 
could not be well-estimated (>50% RSE) and the overdispersion parameter of the 
Negative Binomial model was near the lower bound of 0. Approximate equidispersion 
observed from the data (Figure 2.1 lower panel) corroborates with the lack of 
improvement with these two models and poor estimation of the dispersion parameter.  
Based on the lack of improvement in fit for the Poisson model, and the lower AIC of the 
model assuming continuous data compared to Poisson model, the continuous variable 
model was selected.  
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2.2.4 Model Evaluation 
The bootstrap analysis results including confidence intervals are summarized in Table 
2.2. All of the 1000 bootstrap analyses successfully converged, indicating model stability, 
and were included in the summary. The bootstrap showed narrow confidence intervals for 
all parameters and the median values of the parameters from the bootstrap are 
comparable to the final model estimates from the original dataset, suggesting these values 
are reliable.  
The results of the visual predictive checks (Figure 2.5) indicates the adequacy of the final 
models in describing the central tendency and variability of the observed data. 
2.3 Discussion  
This report provides the first description of the pharmacokinetic-pharmacodynamic 
relationship between topiramate plasma concentrations and SDMT, a sensitive measure 
of topiramate-induced impairment of attention, working memory and psychomotor speed. 
Established on data pooled from three randomized, crossover studies in healthy subjects, 
an inhibitory Emax model was found to characterize the topiramate concentration-SDMT 
score relationship well. At the EC50 of 2.85 µg/mL, this topiramate plasma concentration 
value was estimated to be associated with a 25.5% reduction of SDMT score relative to 
baseline.  Moreover, to our knowledge, this is the first characterization of the practice 
effect due to repeated administration of the SDMT over intervals as short as a week. 
In this analysis, age was an important determinant of the baseline SDMT score, with an 
estimated decrease of 1.13% in baseline SDMT score with every year increase in age. 
This is consistent with other reports of a SDMT performance decline in normal aging. In 
particular, a study conducted in older individuals undergoing coronary bypass graft 
surgery (n=239, mean age of 67.2 ±8.7), reported a similar SDMT score decline rate of 
approximately 1.26%.(23) Based on normative data from a study in homosexual/bisexual 
men ranging in age from 25 to 54 years (n=733), a significant association (p<.0001) 
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between age and SDMT test performance has also been previously demonstrated.(24) In 
addition, summary of SDMT data from several studies in healthy subjects also suggests a 
decrement of SDMT performance in older individuals, with a mean score of 58.2 
(SD=9.1) reported for individuals less than 30 years old, 53.2 (SD=8.9) for individuals 
between 30 to 55 years old, and 35.8 (SD=9.6) for individuals over 55 years old (25).  
Notably, improvements in SDMT score were observed with multiple administrations of 
the test when topiramate was not given, indicating the presence of a practice effect, which 
refers to gains in test scores due to the subject’s increasing familiarity with the testing 
procedure. This practice effect was accounted for in our model by inclusion of NPT as a 
dichotomous variable on baseline SDMT score, and a significant increase in test scores 
was found upon the third administration of the test. This is consistent with the findings 
from an earlier study in 54 healthy subjects, which reported significant increase in SDMT 
score between the second and third test administration (26). It should be noted that the 
duration between tests for that study was 18 months while the testing intervals in our 
studies ranged from hours to two months. 
Repeated neuropsychological testing over time intervals as short as hours to weeks may 
be necessary in designs aimed at investigating the acute effect of drug concentration on 
neurocognitive function within an individual.  While our approach allowed us to 
characterize the practice effect of SDMT administered multiple times within close 
temporal proximity, with the unequal time intervals between drug-free test sessions 
resulting from the randomization and pooling of data across study designs, modeling of 
the change in drug-free SDMT score as a function of time may be a preferred approach. 
However, due to the limited time-points for which SDMT scores were collected under 
drug-free conditions, we were unable to employ a time-dependent approach, which is a 
limitation of this analysis. 
Nevertheless, despite the practice effect that led to improvement of SDMT scores, 
administration of a single dose of topiramate worsened performance on the SDMT and 
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the mean SDMT score declined nonlinearly with increasing topiramate plasma 
concentration. At the typical peak topiramate concentration of 2 µg/mL, observed after a 
dose of 100 mg, an average reduction of 21% in SDMT score relative to the initial 
baseline is predicted from the model. This decline in attention, working memory and 
psychomotor speed, as measured by the SDMT, can be attributed to exposure to 
topiramate alone since the study population included only healthy subjects, thus 
eliminating confounding variables such as seizures, drug interactions and the underlying 
pathology of epilepsy. In general, these findings are in line with previous reports of the 
cognitive effects of topiramate in healthy subjects. In one study on healthy volunteers 
with comparable demographics (mean age (range) = 37 (22 to 58) years) as that in our 
study, the mean SDMT baseline score was 62.1 compared to the typical score of 59.3 in 
this study (14). Interestingly, based on the average topiramate plasma concentration of 
9.3 µg/mL reported after titration and multiple dosing to steady-state at 300 mg/day 
topiramate by Meador et al., our model predicts an average drop of 39% in SDMT score, 
which is higher than the observed average drop of 25.4% in that study (14). Other than 
the possibility that the model may be inadequate at predicting the effect on SDMT at high 
doses, since we have only studied up to 200 mg, it is also possible that tolerance to the 
cognitive side effects may have developed with slow titration over the seven-week 
treatment duration in that study. The latter would be consistent with findings of an 
increase in cognitive side effects with rapid titration schedules in patients with epilepsy 
(26,27). Studies designed to examine acute and chronic effects of topiramate on SMDT 
score, however, would be needed to verify this.  
It is worth mentioning that the narrow range of administered doses and concentrations in 
our study were limitations to investigating the PK-PD relationship at higher exposures to 
topiramate. In addition, collection of SDMT data at more time-points following placebo 
treatment is needed for characterization of the time course of the practice effect. 
Randomized, placebo controlled crossover studies using a wider range of topiramate 
doses and intensive PK-PD sampling are now underway in order to address these 
limitations.  
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In conclusion, we used a PK-PD modeling approach to characterize and quantify the 
exposure-response relationship of doses (100 or 200 mg) of acutely administered 
topiramate with SDMT scores in healthy volunteers. While it is unclear if this 
relationship can be directly translated to patients with epilepsy, these results may be 
relevant for patients with migraine or individuals who are taking these doses of 
topiramate for obesity. Moreover, this approach enabled the quantification of the practice 
effect observed with repeated administration of neuropsychological tests over shorter 
testing intervals than have previously been reported in the literature.  
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Table 2.1  Study Demographics 
 Study I Study II Study III Total 
N 10 9 11 8 38 
Dose (mg) 100 100 100 200 - 
Body weight (kg) 1 
79.8 
(58.30-112.3) 
72.27 
(54.70-92.3) 
78.76 
(59.80-111.2) 
77.6 
(52.2-104.4) 
77.6 
(52.2-112.3) 
Age (years) 1 31.5 (19-55) 22 (20-24) 31 (20-50) 30.9 (19 - 53) 26.5 (19-55) 
Sex 6 M, 4 F 7 M, 2 F 7 M, 4 F 4 M, 4 F 24 M,16 F 
Race (Caucasian/AA/ 
Others/Unknown) 9/1/0/0 6/1/2/0 7/3/0/1 
 
2/5/1/0 26/10/3/1 
1 Median (range) 
AA, African-American; N, number of individuals. 
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Table 2.2 Summary of Continuous and Poisson Population Pharmacokinetic-Pharmacodynamic Model Parameters 
Parameter 
Continuous model Poisson model 
Estimate (RSE%)
Median from 
bootstrap 
95% CI from 
bootstrap 
Estimate (RSE%) 
E0 59.3 (3.2) 59.4 55.7 – 62.9 59.4 (3.1) 
Emax 0.51 (18.3) 0.503 0.26 – 0.76 0.532 (19.9) 
EC50 (µg/mL) 2.85 (20.7) 2.77 0.43 – 5.26 3.07 (34.5) 
߆ே்ாௌ்வଵ 1.07 (2.7) 1.07 1.02 – 1.13 1.09 (2.5) 
߆௔௚௘ -0.0113 (20.4) - 0.0115 -0.0160 – -0.00661 -0.0116 (20.0) 
IIV baseline (%CV)1 18.3 (13.3) 17.3 12.9 – 22.5 18.5 (12.7) 
Proportional residual error (%CV)2 16.2 (7.6) 15.9 13.5 – 18.4 - 
1 Reported as %CV, calculated using equation: 100 ∗ ඥexpሺ݋݉݁݃ܽሻ െ 1 
2 Reported as %CV, calculated using equation: 100 ∗ ඥsigma 
E0, baseline SDMT score; EC50,  topiramate plasma concentration at half of the maximal drug effect ;߆ே்ாௌ்வଵ, proportionality 
constant accounting for difference in E0 for NPT greater than 1; ߆௔௚௘, effect of age on E0; IIV baseline, interindividual variability on 
baseline; RSE%, Percentage relative standard error.
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Figure 2.1 Histogram of Symbol Digit Modalities Test (SDMT) score (upper 
panel) and plot of variance versus mean of SDMT score obtained from raw data 
(lower panel). Each observation (open circle) represents one subject, solid line 
represents the line of identity and the dashed line represents the smoothed loess fit. 
  
 39 
 
Figure 2.2 Relationship between individual baseline (BL) and age. Open circles 
represent observations, and solid line represents the smoothed loess fit, with the 
95% confidence interval around the smooth displayed as shaded area. 
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Figure 2.3 Symbol Digit Modalities Test (SDMT) score change from baseline 
under drug-free conditions for: all studies combined (upper panel) and stratified by 
study (lower panel). The boxes represent 25th, 50th and 75th percentiles, whiskers 
represent the extreme datum within 1.5 times of the inter-quartile range, and the 
black filled circles represent outliers. Numbers above the median lines denote the 
number of individuals.		
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Figure 2.4 Symbol Digit Modalities Test (SDMT) score-topiramate plasma 
concentration profile. Blue open circles denote observations, black line denotes final 
model fit and black triangles denote baseline/placebo observations from third test 
administration onwards. Inset on top right corner shows topiramate plasma 
concentration up to 6 µg/ml.  
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Figure 2.5 Prediction-corrected visual predictive check for the final model, 
stratified by placebo (upper panel) and treatment (lower panel). Open circles 
represent prediction-corrected observations, lines represent 5th, 50th, and 95th 
percentiles of prediction-corrected observations and shaded areas represent 95% 
confidence intervals of the respective prediction-corrected simulated data. 
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CHAPTER 3 
MODEL-BASED CHARACTERIZATION OF SATURABLE 
GABAPENTIN ABSORPTION IN A POOLED POPULATION 
PHARMACOKINETIC ANALYSIS 
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3.1 Introduction 
Epilepsy and neuropathic pain are two common neurologic conditions that affect the 
elderly population. For both conditions, age-related increases in incidence and prevalence 
are known. In the case of epilepsy, the annual incidence of seizure shows a bimodal 
pattern across age with a peak in children less than five years of age (100 per 100,000 
people), and an increase with age from 45 years onwards to a higher peak at age 70 and 
above (147 per 100,000 people), compared to approximately 60 per 100 000 people for 
the general population (1). Neuropathic pain, similarly, disproportionally afflicts older 
patients with several fold higher incidences of postherpetic neuralgia, diabetic 
neuropathy, and phantom limb pain in patients above 75 years old, compared to patients 
between 45 and 59 years (2,3).  
Gabapentin, a structural analog of y-aminobutyric acid (GABA), is commonly prescribed 
for the treatment of partial seizures and neuropathic pain in elderly patients. Unlike many 
anti-seizure drugs, gabapentin has a relatively favorable pharmacokinetics and safety 
profile, with lower propensity for drug-drug interactions since it is not significantly 
metabolized and binding to plasma proteins is negligible (4–8). Two pharmacokinetic 
characteristics of gabapentin that need to be considered, however, are 1) the dependency 
of its elimination on renal function, and 2) saturable absorption of gabapentin through 
system-L transporter uptake in the small intestine, which leads to nonlinear increases in 
the amount of gabapentin absorbed with dosage increment, across the usual clinical dose 
range (up to 4800 mg/day) (4,9–12).  
A previous single-dose pharmacokinetics study of gabapentin in subjects with varying 
renal function had shown that gabapentin exposure increases by over 6-fold in subjects 
with renal impairment (< 30 ml/min), compared to those with normal renal function (10). 
This has implication on gabapentin dosing in the elderly since renal function is typically 
reduced as an individual ages, hence dose adjustment may be necessary in the elderly. A 
single dose study in healthy subjects (aged 20 to 78 years) and preliminary results from 
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two studies in elderly patients had indicate that the decline in clearance of gabapentin 
with age can be explained by the age-related decline in renal function, hence only 
adjustment of dosage by renal function is needed (13–15). However, the former study 
was limited by a small range of renal function and the latter, by the narrower age range 
available.   
In addition, preliminary data from a nursing home study suggested that saturation of 
gabapentin absorption may occur at a lower dose than previously reported in younger 
adults (15).  The implication is that given the same oral dose of gabapentin, an elderly 
patient may absorb less than a younger patient, which could result in under-dosing. To 
enhance understanding of these complicated therapeutic issues, the objectives of the 
present work were to better characterize saturable absorption through a population 
pharmacokinetic analysis of a combined database that comprises a wider range of dose, 
age and renal function, and to further explore the importance of age and measures of 
renal function on clearance and saturable absorption. The influence of other demographic 
and/or physiologic determinants on gabapentin pharmacokinetics were also explored. 
3.2 Methods  
3.2.1 Study Design and Data Collection 
A total of 1115 serum/plasma gabapentin concentration data from 285 patients were 
pooled from three sources with different patient population for the pharmacokinetics 
analysis: 1) elderly community-dwelling patients (Department of Veterans Affairs 
Cooperative Study 428 [VA cooperative study 428]), 2) nursing home patients and 3) 
patients of an epilepsy specialty clinic (MINCEP, St Louis Park, MN).  
All studies were approved by the respective local institutional review board (IRB) of each 
participating center and informed consent obtained from patients or their designated 
guardian prior to participation. In addition, approval was obtained from the central VA 
Human Rights Committee for VA cooperative study 428. Retrospective analysis of the 
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MINCEP gabapentin pharmacokinetics data was considered exempt by the University of 
Minnesota IRB as all identifiers were masked.  
VA Cooperative Study 428  
This was a multi-center, randomized, parallel, double-blind trial comparing 
carbamazepine, lamotrigine, and gabapentin monotherapy in the treatment of partial 
epilepsy in elderly veterans (7). Patients ≥ 60 years of age, with a confirmed diagnosis of 
new-onset seizures, at least one seizure per month during 12 weeks before randomization 
were enrolled. Anti-seizure drugs being taken at enrollment (if any) were tapered to zero 
during titration of study drug. Exclusion criteria were history of non-compliance and 
severely debilitating neurological disorders.  
Gabapentin doses were administered orally as three divided daily doses, with initiation of 
therapy at 300 mg/day and titration to a target of 1500 mg/day in increments of 300 mg 
every three days. Blood draws for drug and clinical laboratory (e.g., serum creatinine) 
level measurements were scheduled to take place during regular clinic visits at week 2, 4, 
6, 8, 12, 16, 20, 24, 28 and bimonthly until week 52, at the convenience of the patients, 
and concentrations were assumed to be at steady-state at the time of visit. Demographic 
data including body weight and body mass index (BMI), and dosing information (last 
three doses taken prior to visit and the corresponding date-times of dosing) were 
collected at each visit. Sex, height, race and date of birth were recorded at screening, and 
age was calculated, truncated to the nearest whole number 
Nursing home study 
Patients ≥ 60 years of age, receiving gabapentin treatment, were recruited from seven 
nursing homes located in Minnesota and California for the observational study. Inclusion 
criteria comprised of being on the same dose of gabapentin for at least 4 weeks at the 
time of study entry, and residency at the facility for at least 2 months, therefore it was 
assumed that titration was completed and the gabapentin levels are at steady-state. 
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Comatose subjects or those with unstable medical conditions that would compromise 
their survival throughout the study period were excluded.  
The study design comprised of four visits per patient, over a duration of up to 
approximately 9 months, to collect four steady-state plasma gabapentin concentrations 
each. At each visit, blood samples were taken for the measurement of gabapentin 
concentration and time recorded to determine time after dose. In addition, other dosing 
information and basic clinical laboratory measures (kidney and liver function tests) were 
obtained. Demographic information included date of birth, race, ethnicity, sex, height, 
body weight, and medical history and was recorded at the first visit, and age at each visit 
was calculated. 
MINCEP epilepsy clinic database 
Serum gabapentin concentrations were obtained from a tertiary epilepsy care specialty 
clinic (St Louis Park, MN) database, dated from year 2000 to 2012. These were collected 
as part of routine clinical practice. Demographics (age at clinic visit, sex, body weight 
and height), clinical laboratory values such as serum creatinine measurements, as well as 
dosing information were included in the database, but were not a requirement. For this 
analysis, gabapentin levels with no corresponding last dose date-time or dosing regimen 
information or without record of the date-time of blood draw were excluded. As serum 
creatinine values were needed for the estimation of renal function, gabapentin 
concentrations without a corresponding serum creatinine measurement were also 
excluded from the analysis. Possible datum errors (e.g. implausible weight, date, and 
records with sample collection date-time preceding the last dose date-time) were also 
excluded (Figure 3.1).  
3.2.2 Gabapentin Measurement  
Serum concentrations of gabapentin for VA Cooperative Study 428 were analyzed at a 
central research laboratory by high performance liquid chromatography using a previously 
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developed assay before the completion of the study (16). The lower limit of 
quantification was 0.2 μg/mL.  
For the nursing home study, plasma gabapentin concentrations were quantified by an LC-
MS detection method, validated in our laboratory. 2H4-Gabapentin (GBP-d4, Toronto 
Research Chemicals, North York, Canada) was used as the internal standard. Patient 
samples were prepared using solid phase extraction (SPE) method. The SPE column (1 
mL of Strat-X-CW 33 uM 30 mg/ 1mL; Phenomenex, Torrance, CA) was pretreated with 
100% methanol followed by Millipore water and centrifuged at low speed (500 rpm) after 
each treatment. A mixture of 50 μL of patient plasma and 400 μL of internal standard 
were loaded to the pretreated SPE column, centrifuged at 500 rpm for 30 seconds and 
washed with 500 μL Millipore water followed by a one-minute centrifugation at 500 rpm. 
Samples were then eluted in a three-step process with 500 μL of 2% formic acid in 
methanol, dried under nitrogen at 36 degree C, reconstituted in 1000 μL of the injection 
buffer (methanol: formate buffer 20:80), and centrifuged at 10,000 rpm for 10 minutes. 
The mobile phase consisted of a mixture of two components: the first included 10 mM 
formate buffer with 1.25 mM heptaflourobutyric acid (HFBA; pH 3.0), while the second 
comprised 100% methanol with 1.25 mM HFBA, and was run at a constant flow rate (0.4 
mL/min) with a gradient design that varied the percentage of the second solution from 
15% to 45% over a time period of 7 minutes. All samples from an individual patient were 
run at the same time along with 6-concentration standard curve (linear range 0.27 – 21.35 
μg/mL) and low, medium and high concentrations of quality control samples. The assay 
had an acceptable limit of precision with %CV <5% at the upper limit of quantification 
and <10% at the lower limit of detection. 
For the epilepsy clinic database, serum gabapentin concentrations were determined by 
immunoassay at MedTox Laboratories (St. Paul, MN, U.S.A) as part of clinical care. The 
MedTox assay had a lower limit of quantification of 0.5 μg/mL. 
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3.2.3 Population Pharmacokinetic Modeling 
Population pharmacokinetic analysis of gabapentin was performed using nonlinear mixed 
effects modeling with NONMEM (version 7.2, ICON Development Solutions, Hanover, 
MD, USA), using first-order conditional estimation (FOCE) method, with ETA-
EPSILON (η-ε) interaction. Diagnostic graphics and exploratory analyses were done with 
R (version 3.1.0) (http://www.r-project.org) and Xpose (version 4.3.2) 
(http://xpose.sourceforge.net).  
Individual pharmacokinetic parameters were assumed to be log-normally distributed and 
the inter-individual random effects were modeled using an exponential error structure. 
Different error structures (proportional, additive and combined proportional/additive) 
were explored for the within-subject variability (residual variability). Separate 
estimations of residual errors for the different studies were also examined, to allow for 
inter-study differences such as different assay and data collection rigor, but these were 
found to be similar, hence a combined residual error model was used. Goodness of fit of 
the candidate models was evaluated using graphical assessment, and histograms of the 
empirical Bayes predictions of the inter-individual random effects were inspected to 
verify that the statistical assumptions were met (i.e. unimodal and symmetrically 
distributed around zero). 
3.2.4 Covariate Assessment 
Covariates were evaluated by stepwise forward inclusion and backward elimination, with 
forward inclusion criteria of p≤0.01 (objective function value (OFV) drop of at least 6.64 
for one degree of freedom) and backward elimination criteria of p≤0.001 (OFV increase 
of 10.83 for one degree of freedom), based on the likelihood ratio test. Visual inspection 
of goodness of fit and covariate versus ETA plots were also used to guide covariate 
modeling. Covariates assessed in this analysis included dose, total daily dose, age and 
measures of renal function (estimated GFR [eGFR] calculated using the Modification of 
Diet in Renal Disease (MDRD) equation, and creatinine clearance [CrCl] calculated 
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using Cockcroft–Gault formula (17,18). Race (African-American/Non-African 
American), a required field in the calculation of eGFR, was unavailable in the epilepsy 
specialty clinic database for this analysis and imputed as non-African American, based on 
information from the neurologist that the majority of patients (>90%) from the clinic 
were non-African American. The effect of dose and total daily dose (TDD) on the extent 
of absorption were explored through a nonlinear function on bioavailability (Equation 1): 
ܨ ൌ 1 െ	ቀி೘ೌೣ	ൈ஽௢௦௘஽ఱబା஽௢௦௘ ቁ      (Equation 1) 
where Fmax is the reduction in extent of absorption at maximal saturation, and D50 is the 
dose or TDD at which the absorption is half saturated. Inclusion of a Hill constant, which 
controls the sigmoidality of the mathematical function, was also examined. The influence 
of other continuous covariates (CrCl, eGFR and age) on clearance was explored using 
power models, with the covariate scaled by the median value. Age was modeled both as a 
continuous and categorical covariate on D50 to investigate possible differences in 
saturable absorption between the elderly and younger adult patients. In the examination 
of age as a categorical covariate, different cutoff ages (60, 65 and 70 years) that 
correspond to typical definitions of elderly were used.  
Reports in the literature suggest that the nursing home elderly population in general are 
physically frailer, suffer from more comorbidities, and receive more medications than 
community dwelling elderly patients (19–22). As these factors may affect 
pharmacokinetics, we examined patient status (i.e., nursing home elderly versus 
community dwelling elderly) as a possible covariate on pharmacokinetic parameters of 
gabapentin.    
3.2.5 Model Selection and Assessment 
Model selection was based on differences in NONMEM objective function value (OFV) 
for competing nested models using the likelihood ratio test, graphical diagnostics using 
goodness-of-fit (GOF) plots, precision of parameter estimates and plausibility of the 
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parameter estimates. Akaike’s Information Criterion (AIC) was considered for non-
nested models. Evaluation of the final model was performed by prediction-corrected 
visual predictive checks (pc-VPC), using Perlspeaks-NONMEM (PsN) (version 3.6.2), 
based on 1000 simulations (23).  
Precision of the final model parameter estimates was assessed using both the asymptotic 
standard errors obtained by the covariance routine in NONMEM, and nonparametric 
bootstrap performed using PsN. From the original dataset, 1000 bootstrap datasets were 
constructed by repeated sampling with replacement and the final model was fitted to each 
of the bootstrap dataset. The median and the 2.5th and 97.5th percentiles were then 
obtained for each pharmacokinetic parameter and 95% confidence intervals based on the 
percentiles obtained.  
3.2.6 Sensitivity Analysis 
As the use of body weight in the Cockcroft-Gault formula may overestimate renal 
function in the morbidly obese (BMI>40 kg/m2) and to a lesser extent, obese (BMI>30 
kg/m2) population, and lean body weight (LBW) had been proposed by some as a better 
substitute, sensitivity analyses were conducted to determine the impact of the use of the 
original Cockcroft-Gault formula, compared to modifications made based on BMI 
(MCrCl and MCrCl2) as shown in Equation 2 and 3 (24). 
ܯܥݎܥ݈ ൌ ሺଵସ଴ି஺௚௘ሻሺ௅஻ௐ	௜௙	஻ெூவସ଴	௢௧୦ୣ௥௪௜௦௘	௕௢ௗ௬	௪௘௜௚୦୲ሻ∗଴.଼ହ	ሺ௜௙	௙௘௠௔௟௘ሻ଻ଶ∗ௌ௘௥௨௠	஼௥௘௔௧௜௡௜௡௘  (Equation 2) 
ܯܥݎܥ݈2 ൌ ሺଵସ଴ି஺௚௘ሻሺ௅஻ௐ	௜௙	஻ெூவଷ଴	௢௧୦ୣ௥௪௜௦௘	௕௢ௗ௬	௪௘௜௚୦୲ሻ∗଴.଼ହ	ሺ௜௙	௙௘௠௔௟௘ሻ଻ଶ∗ௌ௘௥௨௠	஼௥௘௔௧௜௡௜௡௘  (Equation 3) 
 
Typical gabapentin concentration profiles were simulated from the final models based on 
the three different CrCl calculations, under the following scenarios: 70 kg male aged 35 
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or 65 years, BMI of 25, 35 or 45 kg/m2, and steady-state gabapentin dosing of 600 mg 
TID, and the simulated profiles were compared visually.   
3.3 Results 
The demographic and clinical characteristics of the population included in the analysis 
are summarized in Table 3.1, combined and stratified by individual study. Patients 
(N=285) were similarly distributed across all studies for weight and BMI (Figure 3.2). A 
wide range of age and CrCl were available in this combined analysis, with a majority of 
the clinic patients being younger (< 65 years old). As expected, the VA Cooperative and 
nursing home study, which consisted of elderly patients, had generally lower CrCl and 
renal function (Figure 3.2 and Figure 3.3). 
3.3.1 Gabapentin Pharmacokinetic Model 
A one-compartment disposition model with first-order absorption and dose-limited 
bioavailability best described the gabapentin concentration data. The model was 
parameterized in terms of clearance (CL), volume of distribution (Vd), first-order 
absorption rate constant (Ka) and bioavailability (F). Bioavailability was modeled as a 
function of the dose using a modified Emax model. The between subject variability was 
described using an exponential error model and a proportional error model was 
implemented for residual variability. The parameters of the final model were generally 
well estimated with relative standard errors (RSE) of less than 30% (except for D50) and 
shrinkage values were less than 20%. A summary of the population parameter estimates 
from the final pharmacokinetic model and the corresponding RSE are provided in Table 
3.2. 
In the univariate analysis of the covariates, inclusion of the nonlinear function (Equation 
1) to characterize the individual and total daily dose – bioavailability relationship 
significantly improved the model fits, with OFV reduction of 101.9 and 129.9 
respectively. Addition of a Hill constant was not found to significantly improve the 
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model fits. Individual dose, which is a more relevant measure of bioavailability, as 
opposed to TDD, was retained for further covariate assessment. The measures of renal 
function (CrCl and eGFR) were both significant predictors of gabapentin clearance in 
individual assessments (OFV drop >200 for both CrCl and eGFR). However, only CrCl 
was included in the full model due to strong collinearity between these two covariates, 
and the lack of race information, which was needed to calculated eGFR, for the clinic 
database.  
Age on Vd, as well as age (both continuous and categorical) on the dose at which half-
maximal saturation of absorption occurs (D50), were not found to be significant 
covariates. Since it was previously reported that there appeared to be a trend towards 
decline of gabapentin Vd with increase in age in men but not women, albeit not 
statistically significant, further exploration of the age and Vd relationship within men was 
done in this analysis, but no difference could be discerned (13). Inclusion of age as a 
continuous covariate on Vd was not significant in the forward inclusion step. Further 
exploration of this relationship after accounting for dose and CrCl in the final model did 
not yield a significant improvement in the OFV either (drop of 1.6). While decline of CL 
with increase with age was observed, this was not significant after the effect of CrCl on 
CL was accounted for during the backward elimination.  
In this analysis, a total of 218 out of 285 patients were aged 65 and above. Within this 
group of elderly patients, 75 patients were from the nursing homes and 143 were 
community dwelling. Addition of patient status (nursing home versus community 
dwelling) as a covariate on CL for elderly patients did not improve model fit. While a 
smaller typical Vd (3% decrease) and larger inter-individual variability was estimated for 
the nursing home group, when differences between typical Vd and separate inter-
individual variability of Vd were included in the model for non-elderly, community 
dwelling and nursing home elderly patients, these additional parameters could not be 
well-estimated (RSE>100%). Furthermore, the addition of random effects were 
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associated with high shrinkage values, which is indicative of insufficient data for 
estimation of the individual parameters (25). 
3.3.2 Model Evaluation 
The bootstrap confidence intervals are summarized in Table 3.2. Ninety-eight percent of 
the 1000 bootstrap analyses successfully converged, indicating model stability, and were 
included in the summary. The bootstrap showed narrow confidence intervals for all 
parameters and the median values of the parameters from the bootstrap were comparable 
to the final model estimates from the original dataset, suggesting these values are reliable.  
The results of the visual predictive checks (Figure 3.3) indicate the adequacy of the final 
model in describing the central tendency and variability of the observed data. 
3.3.3 Sensitivity analysis 
Simulated gabapentin concentration profiles from all three pharmacokinetic models (with 
CrCl [Model 1], MCrCl [Model 2] and MCrCl2 [Model 3] included as covariate on CL) 
were stratified by age and BMI (Figure 3.5). As expected, simulated concentrations of 
typical 35 and 65 years old male with BMI of 45 kg/m2 tended to be higher for Model 2 
and 3 relative to Model 1, due to the lower creatinine clearance estimated from the use of 
LBW instead of body weight in the Cockcroft-Gault formula. However, for all six 
scenarios, including BMI of 45 kg/m2, the 90% prediction intervals overlapped, 
indicating a lack of appreciable differences between the models, even when between 
subject variability was not taken into account.   
3.4 Discussion 
Despite being widely used in elderly patients due to its lower propensity for drug-drug 
interactions compared to other anti-seizure drugs, information on gabapentin disposition 
in this population is limited. Through the pooling of data from two different studies in 
 55 
 
elderly patients and a sizable clinic database, we report results from a gabapentin 
population pharmacokinetic model developed from one of the largest elderly containing 
databases to date. This combined database, which includes wide ranges of dose, age and 
renal function not only allowed us to further examine these factors that had been 
associated with the disposition of gabapentin, but also explore other potential covariate 
effects that have not been examined (e.g. effect of age on the saturation of gabapentin 
absorption and pharmacokinetic differences between nursing home and community 
dwelling elderly patients).  
One of our main findings was a lack of additional effect of age on gabapentin CL after 
accounting for the effect of CrCl supporting previously published reports from studies 
with narrower ranges of age and renal function (14,15,26). This suggests that dosage 
adjustment based on renal function, as measured by CrCl is appropriate and that no 
further adjustment to account for variation of CL with age is warranted. In this analysis, 
typical apparent clearance (CL/F) was estimated to be 8.6 L/hr for an individual with 
normal renal function (90 ml/min) taking a 400 mg dose, which is comparable to values 
of 10.1 L/hr reported from a 400 mg single dose study in healthy volunteers, and 11.4 
L/hr from a small population pharmacokinetic analysis in patients with normal renal 
function (26,27).  
Similarly, our typical value of Vd at steady state (74.4 L) is in agreement with reports of 
0.91 L/kg and 0.8 L/kg (i.e. 73.7 L and 64.8 L for a typical 80.9 kg individual) in other 
population analyses as well (6,27). While hydrophilic drugs such as gabapentin may have 
lower Vd in elderly patients due to age-related changes in body composition, a study that 
explored the effects of age and gender on gabapentin pharmacokinetics had previously 
found no significant effect of age on Vd, whether it was with combined data or when 
examined separately by gender (26,28,29). Consistent with those findings, age was not a 
significant covariate on Vd in this analysis. Terminal half-life of gabapentin, reported to 
be between 5 to 9 hours in subject with normal renal function, is also comparable with 
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our estimate of 9.3 hours for an individual with normal renal function (CrCl of 90 
ml/min) (30,31).  
To the best of our knowledge, this is the first examination of possible differences in 
absorption saturability between elderly and younger patients. Through the modeling of 
bioavailability with dependence on individual dose incorporated via modified Emax 
functions, individual doses where the absorption process is half saturated (D50) were 
previously reported in an elderly (450 mg) and younger (1120 mg) patient population 
(15,27,32). Here, we explored the possibility that the discrepancy in these values was due 
to age, and found lack of significant improvements in model fits when age was included 
in the model, either as continuous or dichotomous covariates on D50. Notably, these 
small differences of less than 4% (approximately 15 mg) in estimated D50 for the elderly 
versus younger population for all the different age cutoffs, is also unlikely to be clinically 
significant. Moreover, as doses that are prescribed to the elderly population already tend 
to be lower as a result of decreased renal function, the chances that saturation of 
absorption at a lower dose in the elderly would have an impact are low.  
Interestingly, in this pooled analysis, D50 was estimated to be 549 mg, which is lower 
than previous reports (27,32). It is possible that this difference could be due to the wider 
range of doses available in our analysis (50 to 4800 mg/day), which may have allowed 
better characterization of the relationship between dose and bioavailability. It should be 
noted though that bioavailability was assumed to be 1 in this analysis and its change with 
dose modeled, since actual bioavailability was unavailable due to lack of data on the 
amount excreted in urine. Other than the effect of dose (i.e., decrease in bioavailability 
with increase in dose), a number of factors such as food, genotypic variations in the 
intestinal transporters, and co-medications that interact with the intestinal transporters or 
alter gut transit time, may affect the extent of absorption of gabapentin, and could have 
contributed to this difference in D50 estimation.  
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Previous studies of gabapentin bioavailability had reported between subject variability 
varying from 27.6% in a 600 mg single dose study, to as much as 55% and 57% in 
another study administering 3600 mg/day and 4800 mg/day (12,33). Albeit clinically 
insignificant, food, in particular a high protein meal, is known to have an effect on 
exposure of gabapentin, with an increase of approximately 10% compared to fasting 
(4,34,35). In the current analysis, as well as those previously reported, information on the 
timing of meals was unavailable and we could not account for a food effect. Implicated in 
the gut transportation of gabapentin, are system L transporters located on the basolateral 
membrane of enterocytes: LAT1 and LAT2, as well as the organic cation transporter, 
OCTN1, which is located on the apical membrane. Whilst bioavailability of gabapentin 
was found to be unaffected by OCTN1 genotype, which is consistent with reports that 
LAT-mediated transport is the limiting factor, the influence of LAT1/2 genotypes on 
bioavailability has not been investigated yet (11,36,37). Of interest, while expression and 
activity of intestinal LAT1 has not been investigated in the elderly, LAT1 basal 
expression in skeletal muscle was reported to be similar in young and older adults (young 
28 ± 2 years; old 68 ± 2 years) (38).  
In addition to possible genetic differences that may translate to inter-individual variability 
in LAT-mediated transport, the usage of co-medications that interact with the transporters 
is another possible confounding variable in this and other analyses. Clinically, no 
medication is known to impact gabapentin absorption through interaction with LAT1/2 
transporters in the small intestine. However, at least one in vitro study suggests that 
gabapentin transport by LAT1 can be inhibited by agents such as fenclonine and acivicin 
in a LAT-1–overexpressing cell line (39). While aging is generally associated with 
decreases in gastric motility, and hence can theoretically increase time available for 
absorption thus producing a seemingly higher D50 or Fmax in the elderly, no differences 
were found in the current study (29). This suggests that small differences in exposure 
time to the transporters may not be important, which is in agreement with the hypothesis 
that influx through the apical membrane of enterocytes occurs rapidly (36). Nonetheless, 
it cannot be ruled out that co-medications that greatly prolong gut transit time may still 
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affect gabapentin absorption. For example, it has been demonstrated that administration 
of a 600 mg dose of gabapentin with oral morphine can increase bioavailability of 
gabapentin by 50% (40).   
Besides absorption, membrane transporters may also play an important role in renal 
secretion of gabapentin. In particular, renal clearance of subjects homozygous for the 
OCTN1 deficient allele L503F, was reported to be close to GFR, whereas subjects 
homozygous for the reference allele had larger clearance, which was indicative of net 
secretion of gabapentin in the kidney (37). In this analysis, we were unable to detect 
bimodal distribution of CL and mixture model failed to identify a subpopulation with 
lower clearance. It is possible that the nonlinear relationship we observed between CrCl 
and CL, and had described in the model, may have partly masked this. To further explore 
the role of OCTN1 polymorphism on renal clearance, genotyping would be needed. In 
our exploration of differences between nursing home and community dwelling elderly 
patients, no differences in pharmacokinetics of gabapentin were discernible. However, 
there were some indications of larger inter-individual variability in Vd of gabapentin in 
the nursing home population that may be reflective of larger heterogeneity in the 
conditions of nursing home patients. It should be emphasized though that this is limited 
by insufficient data to properly characterize the inter-individual variability of Vd in this 
analysis. Furthermore, since all the nursing home patients were from one study, study-
specific factors may be confounding, and limit generalizability.  
In conclusion, these results support previous publications that gabapentin CL is 
dependent on renal function, and that dose adjustment should be considered in patients 
with reduced CrCl. No additional effect of age on CL was found. Age was also not a 
significant covariate on Vd and D50.  
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Figure 3.1 Data exclusion flowchart for MINCEP clinic database 
 
 
MINCEP clinic database 
1018 gabapentin concentrations 
(222 patients)
Excluded data without dosing information (e.g., missing dosing 
regimen or last dose date/time) and data error (e.g., implausible 
weight, date and dose amount)
626 gabapentin concentrations (142 patients) retained
Excluded data without associated creatinine clearance value
179 gabapentin concentrations (84 patients) retained 
Excluded records with discrepancy between last dose time and 
sample time (i.e., sample time prior to last dose time), 
ambiguous dose information and highly inconsistent data (e.g., 
concentrations associated with unusually large time from last 
dose that are inconsistent with the rest of the patient’s data ) 
and patients < 18 years old
146 gabapentin concentrations (78 patients) retained
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Table 3.1 Summary of patient demographics 
 VA study 428 
Nursing 
home MINCEP Total 
Total number 132 75 78 285 
Body weight (kg) 1 83.2 
(45.5-153.6) 
74.3 
(39.1-168.6) 
78.9 
(46.0-167.4) 
80.9 
(39.1-168.6) 
Age (years) 1 73 
(59-91) 
81 
(61-98) 
38 
(18-76) 
73 
(18-98) 
eGFR 
(ml/min/1.73m2) 1 
66.2 
(21.6-164) 
65.3 
(13.7-262) 
93.3 
(36.2-194) 
68.7 
(13.7-262) 
CrCl (ml/min) 1 69.8 
(21.6-168) 
56.5 
(16.3-286) 
117 
(43.3-368) 
70.7 
(16.3-368) 
MCrCl (ml/min) 1 69.6 
(21.6-167) 
55.0 
(12.7-286) 
117 
(43.3-368) 
69.6 
(12.7-368) 
MCrCl2 (ml/min) 1 59.1 
(20.1-167) 
48.0 
(12.7-189) 
108 
(35.3-368) 
59.6 
(12.7-368) 
Total Daily Dose 1 
(mg) 
1500 
(900-2400) 
600 
(50-3000) 
2400 
(300-4800) 
1500 
(50-4800) 
Sex 123 M, 9 F 20 M, 54 F 42 M, 36 F 185 M, 99 F 
1 Reported as median (range) 
eGFR = estimated glomerular filtration rate; CrCl = creatinine clearance calculated using 
original Cockcroft Gault formula; MCrCl = creatinine clearance calculated using 
modified Cockcroft Gault formula for individuals with BMI>40 kg/m2; MCrCl2 = 
creatinine clearance calculated using modified Cockcroft Gault formula for individuals 
with BMI>30 kg/m2. 
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Table 3.2  Summary of gabapentin population pharmacokinetic model 
Parameters 
Model 1: 
Cockcroft without 
modification
Model 2: 
Modification for 
BMI>40
Model 3: 
Modification for 
BMI>30
Estimate (RSE%) 
[95% CI]3 
Estimate (RSE%) 
[95% CI]3 
Estimate (RSE%) 
[95% CI]3 
Ka (hr-1) 0.598 (19.7) [0.382 – 0.921] 
0.605 (19.5) 
[0.390 – 0.885] 
0.622 (20.3) 
[0.372 – 0.955] 
CL (L/hr) 4.02 (10.8) [2.95 – 4.84] 
4.17 (10.0) 
[3.18 – 4.99] 
4.58 (10.1) 
[3.52 – 5.43] 
ΘCrCl 0.668 (7.0) [0.577 – 0.760] 
0.664 (6.8) 
[0.577 – 0.750] 
0.642 (7.1) 
[0.559 – 0.741] 
Vd (L) 74.4 (19.5) [48.2 - 118] 
75.7 (19.2) 
[51.6 - 119] 
77.8 (19.8) 
[51.4 - 122] 
Fmax 0.833 (13.8) [0.645 – 1.00] 
0.85 (11.2) 
[0.650 – 1.00] 
0.901 (17.3) 
[0.657 – 1.00] 
D50 (mg) 557 (51.5) [146 - 1220] 
614 (52.1) 
[176 - 1330] 
700 (54.1) 
[198 - 1320] 
CL IIV (%CV)1 33.3 (9.2) [27.1 – 39.0] 
32.9 (9.3) 
[26.5 – 38.4] 
33.3 (8.6) 
[27.2 – 38.6] 
Proportional residual 
error (%CV)2 27.5 (4.0) 27.5 (4.0) 27.6 (4.0) 
1 Reported as %CV, calculated using equation: 100 ∗ ඥexpሺ݋݉݁݃ܽሻ െ 1 
2 Reported as %CV, calculated using equation: 100 ∗ ඥsigma 
3 Obtained from nonparametric bootstraps 
Ka = first order absorption rate constant; CL = clearance, ΘCrCl = effect of creatinine 
clearance on clearance; Fmax is the reduction in extent of absorption (bioavailability) at 
maximal saturation, and D50 is the dose at which the absorption is half saturated; IIV = 
inter-individual variability; RSE% = Percentage relative standard error. 
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Figure 3.2 Distribution of key demographics across different studies. Dashed 
lines denote MINCEP study, solid lines denote nursing home study (NH) and dotted 
lines denote Veteran Cooperative Study 428 (VA) 
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Figure 3.3 Renal function status distribution across different studies. Renal 
function categories are based on the Food and Drug Administration (FDA) 
Guidance for Industry for pharmacokinetic studies (41). 
 64 
 
 
Figure 3.4 Prediction-corrected visual predictive check for the final gabapentin 
pharmacokinetic model. Open circles represent prediction-corrected observations, 
lines represent 5th, 50th, and 95th percentiles of prediction-corrected observations 
and shaded areas represent 95% confidence intervals of the respective prediction-
corrected simulated data 
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Figure 3.5 Simulated steady-state gabapentin concentration-time profiles of 600 
mg TID for typical 70 kg man with serum creatinine value of 1 mg/dL at age 35 year 
old (upper panel) and age 65 years old (lower panel) and BMI of 25 kg/m2, 35 kg/m2 
and 45 kg/m2 
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CHAPTER 4                                                                       
PHXNLME: AN R PACKAGE THAT FACILIATES 
PHARMACOMETRICS WORKFLOW OF PHOENIX NLME 
ANALYSES 
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4.1 Introduction 
Pharmacometrics is a scientific discipline that integrates pharmacokinetics, 
pharmacodynamics, pharmacology, physiology, knowledge about diseases, and statistics 
to quantify interactions between drugs and patients using mathematical models (1–3). In 
recent decades, pharmacometric approaches, such as pharmacokinetic-pharmacodynamic 
modeling and simulation, are increasingly being applied in the drug development process, 
and its value in supporting rational decisions regarding drug use and development, is 
emphasized and advocated by the pharmaceutical industry, academia and regulatory 
agencies (1,4–7). The pharmacometrics workflow, however, can be a complicated 
process that involves multiple computational platforms for the execution of integral 
procedures such as data management and exploration, modeling, model 
diagnostics/evaluation, simulation and reporting, and very often multiple iterations of 
these processes are needed.   
Currently, a plethora of software are available for modeling and simulation, including 
NONMEM, the first software developed for population pharmacokinetic modeling that 
has continued being popular amongst pharmacometricians, Phoenix NLME, R NLME, 
Monolix, ADAPT, SAS NLMIXED procedure, and WinBUGS (8–13). With the limited 
or lack of built-in capabilities of some modeling dedicated software (e.g. NONMEM) for 
data management and exploration, as well as post-processing of modeling and simulation 
output, additional software such as R, SAS, Splus etc, are often employed to perform 
these tasks, and this often requires some programming skills. To increase efficiency in 
the conduct of these pharmacometric processes and also reduce the programming burden, 
several helper tools have been developed. For example, graphical user interface-based 
(GUI) applications such as Pirana, PDx-POP and Census provide integrated 
environments for generation of summaries, management of different model runs, and 
allows utilization of other tools such as PsN and Xpose for functionalities that include 
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bootstrap, predictive checks and generation of graphical diagnostics and data exploration 
(14–17).   
With the exponential growth of the R user and package developer community, one main 
reason being the rich functionalities available within the R package ecosystem that new 
developers can tap into, a number of these helper pharmacometrics tools are being 
developed as R packages. This includes NONMEM specific tools such as Xpose, which 
allows generation of plots for model diagnosis and data exploration, and metrumrg, 
which facilitates the pharmacometrics workflow through a spectrum of functionalities 
(15,18). The latter ranged from data preparation functions such as imputation of missing 
values, modeling and simulation functions such as easier performance of bootstraps and 
simulation with uncertainty, to output visualization and reporting (18). Similar to Xpose, 
PKgraph and PKreport R packages provide model diagnosis and visualization features for 
NONMEM, Monolix, SAS NLMIXED and R NLME output, while packages like 
SAEMIX and R2winbugs provide additional features for modeling using the Stochastic 
Approximation Expectatation Maximization (SAEM) algorithm and the Bayesian 
approach respectively (19–22). 
Phoenix NLME, another popular population modeling software that was first release in 
2009, unlike modeling programs like NONMEM, provides an integrated environment for 
modeling and simulation as a desktop software. It has a user-friendly GUI and provides 
the option for building a model graphically by drawing and connecting blocks, with 
automatic generation of domain-specific language, as well as textually by writing 
differential equations. Full analysis traceability and visual workflow for project 
organization are some advantageous features of this software as well. However, while 
built-in graphical diagnostics for models are automatically generated from this software, 
making it easier for users to perform model assumption checking and assess the model 
performance, there is limited customizability. Often, users are required to regenerate 
some of these plots (e.g. commonly used and published model evaluation such as the 
visual predictive check) in other programs for reporting purposes. Furthermore, multi-
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tasking capability is lacking in this desktop software (i.e. cannot perform concurrent runs 
of two models).     
Leveraging on sophisticated and flexible graphing R packages such as ggplot2 and lattice 
for static graphics and manipulate for interactive graphics, the Phxnlme R package was 
developed to address these shortcomings and implement the analytical workflow of 
Phoenix NLME through the freely available R software (23–25). Through management 
of different model runs or projects using separate R consoles (e.g. different R projects), 
simultaneous runs can also be achieved. Besides these features for improved efficiency, 
as well as more customizable and larger selection of higher quality graphical diagnostics 
and exploratory plots, the Phxnlme R package essentially aims to provide an integrated 
platform for Phoenix NLME modeling, performance of model diagnostics, simulation, 
and bootstrap. Description of the basic workflow followed by details of the 
functionalities of this R package will be provided in the following sections. Using a 
gabapentin pharmacokinetic model as an example, implementation of the Phoenix NLME 
analysis workflow through the Phxnlme R package will also be illustrated. 
4.2 Overview of Phxnlme workflow and folder structure 
Shown in Figure 4.1 is a summary of the Phxnlme workflow, which starts with execution 
of the model run with provision of the data, model file and a column mapping file (a file 
that defines the association between the column headers in the data with the model 
variables in the model file) within the model folder, followed by options to generate a 
variety of basic model diagnostics and exploratory plots, visual predictive checks and 
bootstraps of the model. With the default option of generation of the plots as pdf files, 
both graphical and tabular output will be stored under a Results folder created within the 
model folder. Otherwise, plots will be displayed on the R interface and only the tabular 
output will be stored in the Results folder.  
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4.3 Phxnlme functionalities 
Phxnlme R package content can be broadly categorized into four main functions – 
modeling, diagnostics, visual predictive checks and bootstrap. Documentation and 
examples for the various functions can be accessed from the online user manual on the 
CRAN server (https://cran.r-project.org/web/packages/Phxnlme/index.html ; also see 
Appendix) or directly within the R console by entering ?function (e.g. ?phxnlme, 
?phxplot and ?bootmodel), after installation of the Phxnlme R package.  
4.3.1 Modeling 
Various estimation methods are available for modeling using the phxnlme() function. 
This includes expectation maximization methods like Quasi-Random Parametric 
Expectation Maximization (QRPEM) [method=1], Iterative Two-Stage - Expectation-
Maximization (IT2S-EM) [method=2], which can be used to obtain better initial 
estimates for other methods, FOCE Lindstrom-Bates (FOCE L-B) which may be 
appropriate for observational data that are continuous and modeled with a Gaussian 
likelihood [method=3], first order (FO), where approximation linearize around ETA of 0 
[method=4], First Order Conditional Estimation - Extended Least Squares (FOCE ELS), 
which is similar to NONMEM FOCE with interaction [method=5] and lastly naïve 
pooled, where no interindividual variability is taken into account [method=6] (26).  
Prior to execution of Phoenix NLME model runs on the R interface, three items are 
required: the dataset, the model file and the columns mapping file. These items are 
expected within the model run folder and specification of each item is outlined in the R 
help files, with complete details and examples available within the Phoenix Modeling 
Language Reference Guide and Examples folder provided with the Phoenix NLME 
installation. In this following example using the phxnlme() command, the specified model 
in folder final_run is ran via the default FOCE ELS method with maximum iteration limit 
of 1000.  
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path="C:/Project A/final_run" 
model.file="model.mdl" 
cols.file="cols.txt"  
data="projectA_data.csv"  
phxnlme(path=path,model.file=model.file,cols.file=cols.file,data=data) 
Output from the Phoenix NLME run, produced in the program specific format, is 
additionally parsed by the phxnlme() function to produce a report-friendly Excel 
summary file of the parameter estimates, and presented in the Results folder (C:/Project 
A/final_run/Results in example above). Modification of the command to 
phxnlme(path=path,model.file=model.file,cols.file=cols.file,data=data,method=4) 
changes the estimation method to first order.    
4.3.2 Graphical Diagnostics 
Graphics is an important and powerful tool to explore data and perform model 
diagnostics for model development, as well as to communicate the results (27). In 
Phxnlme, several plots can be selected to help users assess the model fit (Table 4.1). The 
phxplot() function allows generation of: 1) basic goodness of fit plots that help check 
modeling assumptions and assess the model fit (e.g. weighted (WRES) and conditional 
weighted (CWRES) residual scatterplots and scatterplots of observations versus 
predictions), 2) parameter related plots that examine distribution of parameters through 
histograms and quantile-quantile plots, relationship of the parameters with each other 
through correlation matrix plot, and relationships of the parameters with continuous 
covariates through scatterplots and with categorical covariates through boxplots, as well 
as 3) individual model fits.  
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With the phxplot() function, options are available to generate some plots on the same 
page to allow for easier comparison, as well as plotting on log scale for observation 
versus predictions plots and individual model fits to allow for better visualization of data 
that span larger ranges. Using interactive graphic functionalities provided by the 
manipulate package for RStudio, individual model fits can also be viewed dynamically 
on an individual basis. For example,  
phxplot(phxd=ex1,plot.type="ind.dynamic",sel.ID=39) 
generates Figure 4.2, which is the individual model fit of patient ID 39 on the RStudio 
interface. In cases where users have data span over a longer duration (e.g. multiple dosing 
twice daily over 7 days), and would like to better visualize short segments (e.g. 
absorption phase) of the profile fits, the slider on the x-axis of this function provides a 
useful facility to zoom in and out on the graphic.  
Correlation matrix plot of ETAs (empirical-based estimates of the random effects) from a 
pharmacodynamic model is illustrated in Figure 4.3, and the corresponding exploratory 
forest plot that displays the spread of individual parameter estimates, for different sex and 
age, is showed on Figure 4.4. It should be noted that typical forest plots display 
confidence intervals of a certain parameter of interest (e.g. odds ratio, regression 
coefficient), or in pharmacokinetic context - different measures of drug exposure. In this 
case, we have modified it to provide visualization of the spread of individual parameter 
estimates, in terms of percentiles, for different categorical covariates of interest.       
phxplot(plot.type="correlation") 
phxplot(plot.type="forest",cat.cov=c("sex","age"),sparname=c("E0","EMAX")) 
4.3.3 Visual Predictive Checks 
The visual predictive check (VPC) is based on graphical comparison of different 
percentiles of the observed data with the corresponding percentiles derived from 
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simulated data defined by the model, and is widely used as a diagnostic tool in population 
pharmacokinetic/pharmacodynamics modeling to detect model misspecification  (28,29). 
Apart from the traditional VPC, prediction-corrected visual predictive check (pcVPCs) 
further improves ability to diagnose model misspecification, and is particularly useful in 
cases where it is difficult to stratify by covariates or dose (e.g. adaptive study design 
where dose can be adjusted) (30). To generate a VPC/pcVPC using the Phxnlme package, 
the phxvpc.sim() function obtains the parameter estimates from the specified executed 
model run and executes the simulations on the Phoenix engine, based on these parameter 
estimates. VPC plots are then generated from the quantiles of the model predictions and 
observed data with the use of phxvpc.plot(). Options are given in phxvpc.sim() for 
prediction or variance correction, independent variable choice, stratification on important 
variables such as study, sex or dose (up to 3 variables), prediction intervals, various 
binning methods (e.g. K-means, centered, and by user specified bounds), and other 
miscellaneous options such as the setting of seed number for reproducibility. Further 
details are provided within the R help files.  
phxvpc.plot() provides functionality for easy customization of graphical features such as 
axes and title labels, color and size of prediction intervals to create report-ready figures. 
For instance, after specification of 1000 simulations with a seed number of 123 and 
quantiles set at 5th, 50th and 95th using 
phxvpc.sim(path,nsim=1000,setseed=as.integer(123),pi=c(0.05,0.5,0.95)), the following 
commands create four different VPC plots (Figure 4.5): 
1) Without observation points and with the default axis labels 
phxvpc.plot(vpcpath=paste(path,"/vpc_1",sep=""),main.title="VPC 1")  
2) With the addition of observation points and user specified axes labels  
phxvpc.plot(vpcpath=paste(path,"/vpc_1",sep=""), ylab="Concentration", xlab="Time 
after dose",obs.pt=TRUE,main.title="VPC 2")  
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3) With change of symbol for observation points 
phxvpc.plot(vpcpath=paste(path,"/vpc_1",sep=""), ylab="Concentration", xlab="Time 
after dose",obs.pt=TRUE, obs.pch=2,main.title="VPC 3") 
4) Showing different percentiles   
phxvpc.sim(path,nsim=1000,setseed=as.integer(123),pi=c(0.1,0.5,0.9)) 
phxvpc.plot(vpcpath=paste(path,"/vpc_2",sep=""),ylab="Concentration", xlab="Time 
after dose",main.title="VPC 4") 
It should be noted that the current release of Phoenix NLME (version 2.0) has issues with 
reporting of prediction-corrected simulated values and the function for binning by user 
specification. These issues are being addressed and fixes will be available in the next 
release of the software. 
4.3.4 Bootstrap 
Nonparametric bootstrap is a method that is often used for estimation of 
precision/confidence intervals around model parameter estimates (31). In the Phxnlme 
package, performance of bootstrap on the model of interest is carried out using 
bootmodel() and summarization of bootstrap results, in histogram form, can be done 
using bootsum(). Various options, such as the model estimation method, number of 
bootstrap samples, variables for stratification (where up to three variables can be 
provided), and other miscellaneous options such as the setting of seed number are 
available for bootmodel(). The option to stratify a sample by a particular variable, such as 
sex, ensures that each unique value that is available for the selected stratification variable 
will be sampled equally for each bootstrap run. 
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4.4 Phxnlme workflow using gabapentin pharmacokinetic analysis as an 
example 
A pharmacokinetic model of gabapentin is presented as an example in this following 
section, to further illustrate the functionalities of the Phxnlme package. Pooled from three 
different sources for the pharmacokinetics analysis (i.e. studies conducted on elderly 
community-dwelling patients  from Department of Veterans Affairs Cooperative Study 
428 [VA study 428], nursing home patients, and patients from an epilepsy clinic), the 
gabapentin dataset consists of 1115 concentration samples from 285 patients following 
oral administration. A one compartment model with first order absorption, proportional 
residual error model, and dose-limited bioavailability fitted by means of a modified Emax 
function was used to characterize the data using Phxnlme.   
For the purpose of examination of the parameter and covariate relationships, an output 
table file (i.e. parmtable.csv) that requests the empirical Bayes estimates of the 
parameters was specified within the column mapping file (see Appendix). The default 
estimation method of FOCE-ELS, which was proposed to be similar to NONMEM’s 
FOCE method, was selected to allow comparison with the latter.     
Starting with the assessment of the basic goodness of fit of the model, observation versus 
prediction plots and residual scatterplots (Figure 4.6) were requested using 
phxplot(plot.type="obs.pred") and phxplot(plot.type="residual.scatter"). Given an 
adequate structural model, the points of the observation versus prediction plots should be 
evenly spread across either side of the line of identity, and likewise CWRES/WRES 
should also be evenly distributed around the y=0 line for the independent variable (in this 
case, time after dose). Similarly, for the residual error model, no trends should be 
apparent on the residuals versus prediction plots i.e. the spread of points is expected to be 
centered along y=0 across the predictions. As shown in Figure 4.6, no major model 
misspecifications are evident, with the one compartment model and the proportional 
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residual error model. The normality assumption of the ETA distribution was also checked 
by examination of an ETA qqplot (Figure 4.7). 
To explore the relationship of the individual parameters with covariates, Figure 4.8 was 
generated using phxplot(plot.type="param.contcov",cont.cov=c("WT","CRCL","DOSE")) 
and phxplot(plot.type="param.catcov",cat.cov="DOSE"). As illustrated, these plots 
revealed trends toward decrease in apparent clearance with decrease of creatinine 
clearance and increase in apparent clearance with increasing dose. Covariate assessment 
was subsequently conducted, and this included relationships of creatinine clearance 
affecting clearance, as well as nonlinear effect of dose on bioavailability, due to saturable 
uptake by gut transporters. Table 4.2 shows the results after addition of the covariates, 
along with 95% confidence intervals derived from a 1000 sample bootstrap stratified by 
study.  The code for the bootstrap is shown below.  
bootmodel(model="final_crcl",setseed=NULL,clean=FALSE,nboot=1000,bstrat="STDY") 
bootsum(model="final_crcl") 
To evaluate the performance of this model in characterizing the observed data, VPC was 
generated using 
phxvpc.sim(path,nsim=1000,ivar="TAD",setseed=as.integer(123),bin.option="cent",            
bin.center=c(0.03,2.5,3.625,4.5,5.885,9.385,17),pi=c(0.05,0.5, 0.95)). Figure 4.9 
illustrates an adequate description of the central tendency of the data.       
4.4.1 Brief comparison of Phxnlme results with NONMEM results 
Using NONMEM, with helper tools such as PSN and Xpose, the pharmacokinetic model 
of gabapentin was established earlier (Chapter 3). As shown in Table 4.2, the parameter 
estimates from both NONMEM FOCE and Phoenix NLME FOCE-ELS implemented 
through Phxnlme, are similar, with overlapping 95% CI estimated from 1000 
nonparametric bootstraps.   
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4.5 Discussion 
The Phxnlme R package was developed to facilitate the analytical workflow for Phoenix 
NLME analyses. One aim, in particular, was to provide additional customizability and 
improved graphics compared to the output from the current Phoenix platform. Through 
an open-source environment, the package takes advantage of the availability of the well-
designed R user interface and other R packages such as ggplot2 and lattice, to provide a 
comprehensive tool that provides functions for the main modeling activities.  
For novice users, who are unfamiliar with Phoenix modeling language, Phxnlme can 
serve as a supplemental modeling tool for Phoenix NLME, where the initial model 
construction can be done within the desktop software with the aid of the graphical model 
editor (Figure 4.10), or using one of the built-in models (e.g. one-compartment 
pharmacokinetic model, Emax model, linear model) available for selection from the 
dropdown menu. The textual model file and columns mapping file that are automatically 
generated from this initial model build can then be simply used for Phxnlme analysis, to 
make use of the easily implementable, improved and flexible graphing provided by the 
package.  
For more advanced users, Phxnlme can serve as a complete modeling environment, and 
the R platform can be used to carry out the entire modeling process, from data 
manipulation and exploration, to using Phxnlme for modeling, diagnostics, simulation 
and bootstrap. The advantage of this is that the entire workflow can be done and saved as 
an R project or file, easily allowing for reproducibility. Furthermore, with this ability to 
manage different model projects through R projects, different models or projects can be 
worked on simultaneously. This is a major advantage over the desktop version of Phoenix 
NLME, which currently lacks capability for multi-tasking. As the R package is available 
for free, this also provides a benefit over the current work-around for the lack of multi-
tasking function, which involves additional costs to setup a remote processing server and 
additional licensing fees. While it is possible for users to also tackle the multi-tasking 
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issue through running the models using the command prompt, that is not very user-
friendly. 
Phxnlme, like other R packages, is an extensible tool and the hosting of this package on 
an open-source environment makes it easy for adaptation, update and addition of features 
based on feedback from the community, availability of new R packages or package 
functions, and with changes to the Phoenix NLME software. In the current version of 
Phxnlme, model runs cannot yet be implemented on multiple processors. A logical next 
step would be to add on this feature in future to improve on computing time, especially 
for more complex models. Compared to more advanced tools that were developed for 
NONMEM (e.g. PsN), the Phxnlme R package also lacks features such as automated 
covariate search, which will be considered for future updates. Depending on user 
feedback, more customizability for diagnostics plots and greater options for interactive 
graphics and data exploration can also be made available. Creation of a standard output 
object that is compatible with other packages, and upgrade of the plotting function to 
allow plotting of NONMEM results, are potential features for the next version of the 
package as well. 
4.6 Conclusion  
Phxnlme, an R package that implements the pharmacometrics workflow of Phoenix 
NLME, with features for improved and more flexible graphics, is available for download 
for free on the CRAN repository (https://cran.r-project.org/web/packages/Phxnlme/). The 
package requires the Phoenix NLME engine, with valid license, for modeling and 
simulations.  
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Figure 4.1 Phxnlme workflow and folder structure 
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Table 4.1 Plot type options available for phxplot() function 
Options Description 
"correlation" Correlation matrix plots of random effects of parameters 
"obs.pred"  Scatterplots of observations versus predictions with loess smoothed line 
"residual.scatter"  Scatterplots of weighted residuals and conditional weighted residuals versus predictions and time after dose 
"param.catcov"  Boxplots of parameters versus categorical covariates 
"param.contcov"  Scatterplots of parameters versus continuous covariates 
"param"  Histograms of parameters 
"forest" Forest/tornado plots of specified categorical covariates and parameters 
"ind" Individual fits 
"ind.dynamic" Dynamic plots of individual fits 
"qq" Quantile-Quantile plots of parameters 
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Figure 4.2 Example of dynamic individual model fit on Rstudio interface. Upper 
panel displays the dependent variable (DV) – Time after dose (TAD) plot up to 8 
hours, by adjusting the slider on the scale, shown on the left. Lower panel displays 
the dependent variable (DV) – Time after dose (TAD) plot up to the maximum of 36 
hours. Solid line denotes individual prediction, dashed line denotes population 
prediction and circles denote observations.  
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Figure 4.3 Correlation matrix plot of the random effects (ETAs). Circles 
represents the ETAs plotted against each other, lines presents a loess smoothed fit of 
the relationships and the numbers in the upper diagonals denote the correlation 
coefficients. Font size of the correlation coefficient is relative to the strength of the 
correlation. nE0 = random effect on baseline; nEMAX = random effect on maximal 
drug effect; nED50 = random effect on dose at which half maximal effect is 
obtained.      
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Figure 4.4 Exploratory forest plot from a pharmacodynamics model, displaying 
the median (solid circle) and 2.5th to 97.5th percentiles (tails) of the individual 
parameter estimates for E0 and Emax, for different sex and age. Vertical solid lines 
denote the reference point for the population typical values. In this example, age 
was taken as a categorical variable.  E0 = baseline; EMAX = maximal drug effect.  
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Figure 4.5 Examples for visual predictive check (VPC) generated using Phxnlme. 
VPC 1 (upper left panel) shows the default VPC generate with phxvpc.plot(), VPC 2 
(upper right panel) shows a modified VPC with addition of observed concentration 
points, VPC 3 (lower left panel) demonstrates the symbol change function and VPC 
4 (lower right panel) shows the VPC with 10th and 90th percentiles (lines) instead of 
5th and 95th percentiles as in VPC 1.  
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Figure 4.6 Basic goodness of fit diagnostic plots. The top left panel shows the 
observed dependent variable (DV) versus the individual predictions (IPRED), and 
the top right panel shows the observed dependent variable (DV) versus typical 
predictions in the population (PRED). On the lower panel, conditional weighted 
residuals (CWRES) are plotted against time after dose (TAD) on the left, and typical 
predictions in the population (PRED) on the right. In the upper panel, diagonal 
solid lines are lines of identity, and solid lines bounded by the shaded areas are loess 
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smoothed fit with 95% confidence interval displayed around the smooth. Dashed 
and solid horizontal lines in the lower panel are reference lines.  
 
Figure 4.7 Example of ETA qqplot generated to check normality assumption of 
the ETA distribution  
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Figure 4.8 Relationship of the individual clearance estimates (Cl) with body 
weight (WT), creatinine clearance (CRCL) and dose. For the scatterplots, circles 
denote actual predictions and solid lines bounded by the shaded areas are loess 
smoothed fit with 95% confidence interval displayed around the smooth. For the 
boxplot, the horizontal lines within the boxes represent the medians and circles 
denotes outliers. 
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Figure 4.9  Prediction-corrected Visual Predictive Check (pcVPC) of gabapentin 
pharmacokinetic model. Note: Due to a bug in the reporting of prediction-correction 
values in the Phoenix NLME 2.0 (current release as of April 2016), the plot above 
was generated using an Alpha version of the next Phoenix NLME release, which 
includes a fix for this issue. The above-mentioned Alpha version was shared directly 
by the developer of Phoenix NLME (Certara). 
 
 89 
 
 
Figure 4.10 Illustration of the Phoenix NLME graphical model editor applied to a 
one-compartment pharmacokinetic model following extravascular dosing 
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Table 4.2 Summary of gabapentin population pharmacokinetic model  
Parameters 
Phxnlme FOCE NONMEM FOCE 
Estimate (95% CI) Estimate (95% CI) 
Ka (hr-1) 0.598 (0.369 – 0.838) 0.613 (0.382 – 0.921) 
CL (L/hr) 4.29 (1.69 – 5.12) 4.10 (2.95 – 4.84) 
ΘCrCl 0.681 (0.586 – 0.779) 0.665 (0.577 – 0.760) 
Vd (L) 81.0 (26.6 – 110) 77.7 (48.2 – 118) 
Fmax 0.733  (0.624 – 0.984) 0.820 (0.645 – 1.00) 
D50 (mg) 486 (35.4 – 1590) 565 (146 – 1220) 
CL IIV (%CV)1 34.1 (27.7 – 40.4) 33.1 (27.1 – 39.0) 
Proportional residual 
error (%CV)2 28.1 (25.9 – 30.3)  27.5 (25.4 – 29.8) 
1 Reported as %CV, calculated using equation: 100% ∗ ඥexpሺ߱ଶሻ െ 1 
2 Reported as %CV, calculated using equation: 100% ∗ √ߪଶ 
Ka = first order absorption rate constant; CL = clearance, ΘCrCl = effect of creatinine 
clearance on clearance; Fmax is the reduction in extent of absorption (bioavailability) at 
maximal saturation, and D50 is the dose at which the absorption is half saturated; IIV = 
interindividual variability; omega = variance of RSE% = Percentage relative standard 
error.  
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CHAPTER 5 
CONCLUSIONS 
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The overall goal of this dissertation work was to employ model-based approaches for the 
examination and quantification of pharmacological differences in older patients. 
Specifically, the effect of age and age-related factors on the drug disposition and 
tolerability of topiramate and gabapentin were examined and characterized. With the aim 
of facilitating usage of such modeling and simulation approaches for drug development 
and further optimization of dosing for marketed drugs, particularly for elderly patients, an 
auxiliary R tool was also created as part of this dissertation. 
Cognitive impairment is a major challenge associated with the use of topiramate, an anti-
seizure drug that also has indications for migraine prophylaxis and obesity. The extent of 
the impact of cognitive impairment on tolerability of topiramate is evident from the high 
discontinuation rate from the drug due to cognitive complaints such as psychomotor 
slowing and language difficulties (1,2). This was despite similar or better seizure control 
as highlighted in a large clinical study comparing topiramate with other anti-seizure drugs 
such as lamotrigine and levetiracetam (2). In older patients in particular, cognitive 
impairment is a major concern.  
In this dissertation, we examined data pooled from three randomized, crossover studies in 
healthy subjects, ranging from 19 to 55 years old. The relationship between topiramate 
plasma concentrations, following a single dose of 100 or 200 mg of topiramate, and 
cognitive impairment, as measured by the Symbol Digit Modality Test (SDMT), was 
characterized using population pharmacokinetic-pharmacodynamic (PK-PD) modeling. 
From this model, a maximal reduction of 51% in SDMT score was predicted for 
topiramate concentrations that are much larger than the EC50 of 2.85 µg/mL. Age, as 
well as multiple test administration, were also found to be important determinants of 
baseline SDMT score, with an estimated decrease of 1.13% in baseline SDMT score with 
every year increase in age, and improvement in test scores seen after two prior test 
administration.  
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While no clear link between SDMT scores and impact on daily life has been established, 
SDMT scores that are between 1 to 1.5 times below the normative score have been 
considered to be ‘suggestive’ of cognitive impairment and scores below that ‘indicative’ 
of cognitive impairment (3,4). Based on this guideline and taking as an example, a 27 
year old individual with a typical SDMT score of 59, at the peak concentration after a 
100 mg dose of topiramate, the score of this typical individual drops to around 47, as 
predicted from the current model (i.e. a score that puts the individual within the range 
that is suggestive of cognitive impairment) (4). It should be noted however that while 
such criterion, based on variation from the norm, is often included in the screening of 
cognitive impairment for diseases such as multiple sclerosis, rheumatoid arthritis and 
stroke, deficits in cognitive domains other than those assessed by the SDMT also need to 
be considered (5–12). In addition, the clinical significance of the decrease in test score 
will need further consideration.   
In these studies, acute effects were examined after a single dose of 100 and 200 mg, with 
the majority of the data generated from a 100 mg dose. The relatively small 
representation of the 200 mg dose and restricted range of concentrations in our study 
could be limitations to investigating the PK-PD relationship at exposures to topiramate 
that may be more relevant for epilepsy treatment (up to 400 mg/day in two divided 
doses). Additionally, the possibility of developing tolerance to the cognitive effects will 
have to be examined in the future, with a multiple dosing study design. Availability of 
data from older individuals (above 55 years old) may also allow better characterization of 
the age effect for this analysis. 
As the intent of the studies was to examine the cognitive effects of topiramate without 
confoundment from underlying conditions that may contribute to the impairment, we 
explored the PK-PD relationship in healthy subjects. Whether these results can be 
directly translated to patients with epilepsy is unclear. Assuming that the cognitive effect 
of topiramate is additive to that of the underlying cognitive impairment, these results may 
help tease out cognitive impairment due to the underlying condition, if SDMT data from 
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acute treatment with topiramate in epilepsy patients is available. However, in general, 
information in the multiple dosing situation would be more useful since patients are 
typically on chronic treatment. In this analysis, the effect of multiple test administration 
was characterized as a function of the number of prior test administered due to the current 
study designs, which lack of multiple test administrations within a placebo period. This 
approach does not account for differences in test intervals and a possible improvement 
over the current model, is to model this effect as a function of time. To address some of 
these limitations, randomized, placebo controlled crossover studies using a wider range 
of topiramate doses and intensive PK-PD sampling are now underway.  
In the second part of this dissertation, wider dose and age ranges were available for 
gabapentin, an anti-seizure medication that is also used for certain types of pain. A 
pooled gabapentin pharmacokinetics database comprising of a wide range of doses, renal 
function (normal to severe decrease in function) and age (18 to 98 years old) were used to 
investigate the effect of these factors on the pharmacokinetics of gabapentin through 
population pharmacokinetic analysis.  
As previously reported, an important pharmacokinetic characteristic of gabapentin is 
saturable absorption due to dependence on gut transporters, which leads to lack of dose 
proportionality for gabapentin within the typical dose range (13). In this analysis, we 
accounted for this by using a nonlinear function on bioavailability (i.e. extent of 
absorption since metabolism is negligible), and also explored the effects of age on this 
saturability. Consistent with previous reports, gabapentin clearance was found to be 
dependent on creatinine clearance (as measured by the Cockcroft Gault formula) in this 
analysis, and no additional effect of age on clearance was observed after accounting for 
the former (14–16). Age in this analysis, was also not found to affect saturability of 
absorption. With the availability of a relatively large number of elderly patients in this 
dataset, we were also able to examine possible pharmacokinetic differences between 
nursing home patients who could be generally frailer, and community dwelling elderly 
patients. In this covariate analysis, differences between pharmacokinetics of gabapentin 
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in nursing home and community dwelling patients could not be discerned. There were 
indications of higher inter-individual variability for volume of distribution of the nursing 
home population, perhaps due to larger heterogeneity in the conditions of nursing home 
patients, but these inter-individual variability estimates were associated with high 
shrinkage values, hence were not reliable. In addition it cannot be ruled out that study-
specific variables that are unaccounted for may be confounding, since all nursing home 
patients were from one particular study. To further explore this, it may be helpful to 
consider a valid measure of frailty as a possible covariate on the pharmacokinetic 
parameters. In summary, these results support previous publications that gabapentin CL 
is dependent on renal function, and that dose adjustment should be considered in patients 
with reduced CrCl. No additional effect of age on CL was found in this analysis, and age 
was also not a significant covariate on saturability of the absorption. 
For the last section of this dissertation, we addressed the need for an auxiliary tool for 
pharmacometrics analyses done using a popular modeling software, Phoenix NLME, 
through the creation of an R package that provides improved post-processing options, as 
well as offers an integrated platform for key model development activities. Through this, 
we aim to increase the ease modeling and simulation activities can be performed, 
particularly for drug development and further optimization of dosing for marketed drugs 
in the elderly patient population.  
The current Phoenix NLME software, a population PK/PD modeling tool, has a number 
of desirable features such as user-friendly GUI, graphical model building option, analysis 
traceability and ability to organize different modeling tasks or analyses into a workflow 
for project organization. However, there are limitations with regards to customizability 
and quality of the graphical diagnostics and exploratory plots and users often have to turn 
to another software program to improve upon plots that are needed for reporting 
purposes. Furthermore, the current software platform does not allow for multi-tasking 
(e.g. concurrent runs of two different models) on a local machine, which is a major 
limitation especially when dealing with larger datasets and/or more complicated models. 
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To address these shortcomings, the Phxnlme R package was developed. Utilizing existing 
flexible graphing R packages such as ggplot2 and lattice for static graphics and 
manipulate for interactive graphics, higher quality plotting with increased customizability 
was built into the Phxnlme R package. In addition, functionalities for key modeling tasks 
such as basic model diagnostics, visual predictive checks and bootstraps were developed 
for this R package, such that the entire model development process, including dataset 
preparation (not a function within the Phxnlme R package but can be done within R), can 
be performed on the R platform. The capability to create and concurrently run multiple R 
projects further allowed us to address the limitation for multi-tasking on the current 
Phoenix NLME software.  
Phxnlme R package, which was developed as part of this dissertation, is available open-
source on the CRAN repository (https://cran.r-project.org/web/packages/Phxnlme/). To 
ensure usability, documentation and demonstration videos were created, and user 
feedback will be collected to allow us to further improve on the package in the future. In 
conclusion, it is expected that with the additional and improved functionalities that we 
have provided through the development this auxiliary Phoenix NLME tool, the workflow 
of population PK/PD modeling using this software is now easier and more convenient. 
Using the gabapentin analysis as an example, we also demonstrated the possible use of 
this R package for population pharmacokinetic analysis that explores age and age-related 
differences in pharmacokinetics.  
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Appendix 
 
Chapter 2: NONMEM code for population pharmacokinetic-pharmacodynamic 
model 
 
;Description: Emax SDMT FINAL PKPD model (combined) 
$PROBLEM run195r 
$INPUT C ID TIME NTIM DV NPT AMT RATE CMT OCC MDV EVID SEQ TPM  
DRUG WT AGE HT RACE BSA SEX LBM IBW BMI SITE CLI V2I QI V3I KAI F1I 
CP TL 
$DATA 022mod5comb3.csv IGNORE=C; 
$SUBROUTINES ADVAN4 TRANS4 
 
$PK 
CL=CLI 
V2=V2I 
Q=QI 
V3=V3I 
KA=KAI 
F1=F1I 
S2=V2 
 
MED=25.5 
 
IF(NPT.EQ.0.OR. NPT.EQ.1)THEN 
TVBL=THETA(1) 
ELSE 
TVBL=THETA(1)*THETA(4) 
ENDIF 
 
BL=TVBL*EXP(ETA(1))*(1+THETA(5)*(AGE-MED)) 
EMAX=THETA(2)*EXP(ETA(2)) 
EC50=THETA(3)*EXP(ETA(3)) 
 
SID=ID 
TAD=TIME 
 
$ERROR 
CPP=F 
 
E=BL*(1-(EMAX*CPP)/(EC50+CPP)) 
Y=E+E*(ERR(1)) 
IPRED=E 
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IRES=DV-IPRED 
IWRES=IRES/E 
 
$THETA 
(0,60) ;[BL] 
(0,0.4,1) ;[EMAX] 
(0,2.5) ;[EC50] 
(0,1) ;[effect on postBL] 
(-0.02) ;[effect of age on TVBL1] 
 
$OMEGA 
0.1 ;[P] BL 
0 FIXED ;[P] EMAX 
0 FIXED ;[P] EC50 
 
$SIGMA 
0.01 ;[P] sigma(1,1) 
 
$COV 
$EST METHOD=1 INTERACTION PRINT=5 MAX=9999 SIG=3 NOABORT 
MSFO=195r.MSF 
 
$TABLE ID BL EC50 ETA1 ETA3 
NOPRINT ONEHEADER FILE=patab195r 
 
$TABLE ID CP PRED IPRED WRES IWRES RES IRES CWRES TIME TAD OCC 
EVID CPP NPT 
NOPRINT ONEHEADER FILE=sdtab195r 
 
$TABLE ID TIME AGE WT 
NOPRINT ONEHEADER FILE=cotab195r 
 
$TABLE ID SITE SEX RACE 
NOPRINT ONEHEADER FILE=catab195r 
 
$TABLE ID TIME NTIM SID TAD DV CP AMT RATE MDV EVID ONEHEADER 
NOPRINT FILE=195r.tab 
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Chapter 2: NONMEM code for population pharmacokinetic-pharmacodynamic 
model assuming Poisson distribution 
 
;Description: Emax SDMT Poisson model 
 
$PROBLEM run242r 
$INPUT C ID TIME NTIM DV NPT AMT RATE CMT OCC MDV EVID SEQ TPM   
DRUG WT AGE HT RACE BSA SEX LBM IBW BMI SITE CLI V2I QI V3I KAI F1I 
CP TL 
$DATA 022mod5comb3.csv IGNORE=C; 
$SUBROUTINES ADVAN4 TRANS4 
 
$PK 
CL=CLI 
V2=V2I 
Q=QI 
V3=V3I 
KA=KAI 
F1=F1I 
S2=V2 
 
MED=25.5 
 
$ERROR 
IF(NPT.EQ.0.OR. NPT.EQ.1)THEN 
TVBL1=THETA(1) 
ELSE 
TVBL1=THETA(1)*THETA(4) 
ENDIF 
 
TVBL = TVBL1*(1+THETA(5)*(AGE-MED)) 
BL=TVBL*EXP(ETA(1)) 
EMAX=THETA(2)*EXP(ETA(2)) 
 
TVEC50=THETA(3) 
EC50=TVEC50*EXP(ETA(3)) 
 
SID=ID 
TAD=TIME 
 
CPP = F 
 
LAMB=BL*(1-(EMAX*CPP)/(EC50+CPP)) 
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TVLAMB=TVBL*(1-(EMAX*CPP)/(TVEC50+CPP)) 
 
;CALCULATE LL 
 
LFACT = 0 
IF(DV.GT.0) LFACT = -DV + (DV+.5)*LOG(DV) + .5*LOG(2*3.1415) + 
LOG(1+1/(12*DV)) 
 
LL = DV*LOG(LAMB) - LAMB - LFACT 
TVLL = DV*LOG(TVLAMB) - TVLAMB - LFACT 
 
Y = -2*LL 
 
IPRED=LAMB 
 
$THETA 
(0,60) ;BL 
(0,0.4,1) ;EMAX 
(0,2) ;EC50 
(0.1,0.3) ;postBL 
(-0.02) ;AGE 
 
$OMEGA 
0.1 ;eta_BL 
0 FIXED ;eta_emax 
0 FIXED ;eta_ec50 
 
$COV 
$EST METHOD=1 LAPLACE -2LL PRINT=5 MAX=9999 SIG=3 NOABORT 
MSFO=242r.MSF 
 
$TABLE ID BL EC50 ETA1 
NOPRINT ONEHEADER FILE=patab242r 
 
$TABLE ID CP DV PRED IPRED TIME TAD OCC TVLAMB LAMB ETA1 EVID 
CPP 
NOPRINT ONEHEADER FILE=sdtab242r 
 
$TABLE ID TIME NTIM SID TAD DV CP AMT RATE MDV EVID CLI V2I QI V3I 
KAI F1I ONEHEADER NOPRINT FILE=242r.tab 
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Chapter 3: NONMEM code for population pharmacokinetic model of gabapentin 
 
;; Description: GBP PK model, IIV_CL, only CRCL,CRCL, Dose EMAX, adults only 
 
$PROBLEM PK 
$INPUT C ID StudyID=DROP DATE=DROP TIME DV AMT SS II EVID HT WT SEX 
AGE SRCR TDD DOSE BSA BMI IBW CRCL BCRCL RACE LBM EGFR TEGFR 
VISIT=DROP CTD=DROP NTIM=DROP MDV=DROP CBZ=DROP VPA=DROP 
OXC=DROP MOR=DROP ALMG=DROP ALC=DROP NAP=DROP NRHM=DROP 
ETH=DROP EDUC=DROP DCOV=DROP CCI=DROP WEEK=DROP BWGT=DROP 
BUN=DROP REN=DROP GI=DROP CFLG STDY 
$DATA GBP_all3.csv IGNORE=@ IGNORE(AGE.LT.18) 
$SUBROUTINES ADVAN2 TRANS2 
 
$PK 
TVKA=THETA(1) 
KA=TVKA*EXP(ETA(1)) 
TVCL=THETA(2)*(CRCL/65)**THETA(6) 
CL=TVCL*EXP(ETA(2)) 
TVV=THETA(3) 
V=TVV*EXP(ETA(3)) 
FMAX=THETA(4) 
D50=THETA(5) 
F1=1-(FMAX*DOSE/(D50+DOSE)) 
 
S2=V 
 
IF(AMT.GT.0) THEN 
TDOS=TIME 
TAD=0.0 
ENDIF 
IF(AMT.EQ.0) TAD=TIME-TDOS 
 
 
$ERROR 
Y = F+(F*ERR(1)+ERR(2)) 
IPRED=F 
 
$THETA 
(0,0.5) ;KA 
(0,5) ;CL 
(0,50) ;V 
(0,0.5) ;FMAX 
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(0,500) ;D50 
(0,1) ;POW_CRCL 
 
$OMEGA 
0 FIX ;KA 
0.2 ;CL 
0 FIX ;V 
 
$SIGMA 
0.1 ;PROP 
0 FIX ;ADD 
 
$COV 
$EST METHOD=1 INTERACTION PRINT=5 MAX=9999 SIG=3 NOABORT 
 
$TABLE ID CL V KA F1 ETA(2) ETA(3) 
NOAPPEND NOPRINT ONEHEADER FILE=patab406 
 
$TABLE ID DV PRED IPRED WRES RES CWRES TIME EVID TAD STDY 
NOPRINT ONEHEADER FILE=sdtab406 
 
$TABLE ID TIME AGE WT BMI BSA EGFR TEGFR SRCR CRCL TDD DOSE 
NOPRINT ONEHEADER FILE=cotab406 
 
$TABLE ID SEX RACE TDD DOSE STDY 
NOPRINT ONEHEADER FILE=catab406 
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